###begin article-title 0
###xml 22 25 22 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
Joint effects of HLA, INS, PTPN22 and CTLA4 genes on the risk of type 1 diabetes
###end article-title 0
###begin title 1
Background/hypothesis
###end title 1
###begin p 2
###xml 5 8 5 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 21 26 21 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 101 107 101 107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 112 117 112 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
HLA, INS, PTPN22 and CTLA4 are considered to be confirmed type 1 diabetes susceptibility genes. HLA, PTPN22 and CTLA4 are known to be involved in immune regulation. Few studies have systematically investigated the joint effect of multiple genetic variants. We evaluated joint effects of the four established genes on the risk of childhood-onset type 1 diabetes.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 90 98 90 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 101 105 101 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 111 115 111 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 135 138 135 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 140 148 140 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;23&#160;HphI</italic>
###xml 151 156 151 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 158 164 158 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
###xml 170 176 170 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 178 187 178 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg620Trp</italic>
###xml 41 49 <span type="species:ncbi:9606">patients</span>
We genotyped 421 nuclear families, 1,331 patients and 1,625 controls for polymorphisms of HLA-DRB1, -DQA1 and -DQB1, the insulin gene (INS, -23 HphI), CTLA4 (JO27_1) and PTPN22 (Arg620Trp).
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
The joint effect of HLA and PTPN22 on type 1 diabetes risk was significantly less than multiplicative in the case-control data, but a multiplicative model could not be rejected in the trio data. All other two-way gene-gene interactions fitted multiplicative models. The high-risk HLA genotype conferred a very high risk of type 1 diabetes (OR 20.6, using the neutral-risk HLA genotype as reference). When including also intermediate-risk HLA genotypes together with risk genotypes at the three non-HLA loci, the joint odds ratio was 61 (using non-risk genotypes at all loci as reference).
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 159 165 159 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
Most established susceptibility genes seem to act approximately multiplicatively with other loci on the risk of disease except for the joint effect of HLA and PTPN22. The joint effect of multiple susceptibility loci conferred a very high risk of type 1 diabetes, but applies to a very small proportion of the general population. Using multiple susceptibility genotypes compared with HLA genotype alone seemed to influence the prediction of disease only marginally.
###end p 8
###begin title 9
Electronic supplementary material
###end title 9
###begin p 10
The online version of this article (doi:10.1007/s00125-008-0932-0) contains supplementary material, which is available to authorised users.
###end p 10
###begin title 11
Keywords
###end title 11
###begin title 12
Introduction
###end title 12
###begin p 13
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 603 604 603 604 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
The risk of complex diseases such as type 1 diabetes is generally thought to be influenced by multiple genetic and non-genetic factors, and it has been hypothesised that interactions between genes, or epistasis, are very common for such diseases [1]. The presence of interactions could be one of the reasons why searching for susceptibility loci for many diseases has been less successful than expected [2]. When moving from monogenic diseases to complex diseases, it seems reasonable to assess more than one locus at a time, although models become increasingly complex as the number of loci increases [3].
###end p 13
###begin p 14
###xml 97 98 97 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">4</xref>
###xml 363 367 363 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 369 373 369 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 378 382 378 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 459 462 459 462 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 508 513 508 513 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 657 658 657 658 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">5</xref>
###xml 659 660 659 660 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">8</xref>
###xml 390 395 <span type="species:ncbi:9606">human</span>
Whereas few or no common genetic variants have been firmly established for most common diseases [4], there are now at least four genetic loci that are established as causally involved in the aetiology of type 1 diabetes. They give us a unique possibility to evaluate gene-gene interactions among established susceptibility genes. Specific allelic combinations of DRB1, DQA1 and DQB1 in the human leucocyte antigen (HLA) complex, variants in the insulin gene (INS), the cytotoxic T lymphocyte antigen-4 gene (CTLA4) and the protein tyrosine phosphatase, non-receptor type 22 gene (PTPN22) have been repeatedly associated with type 1 diabetes susceptibility [5-8] using different approaches. All established loci are thought to be involved somehow in immune regulation, but details of the mechanisms relating the polymorphisms to risk of type 1 diabetes are in most cases poorly understood.
###end p 14
###begin p 15
###xml 244 245 244 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 247 248 247 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">3</xref>
###xml 250 251 250 251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">9</xref>
Evaluating the joint effects of genes contributes important information for risk prediction, and is also thought to provide information about biological interactions, although the latter is controversial and more complex than commonly thought [2, 3, 9].
###end p 15
###begin p 16
###xml 59 62 59 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 95 97 95 97 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 155 158 155 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 309 311 309 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">19</xref>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2</xref>
###xml 485 487 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">20</xref>
###xml 556 558 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">21</xref>
###xml 589 592 589 592 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 647 649 647 649 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 651 653 651 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 666 668 666 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 732 734 732 734 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 740 742 740 742 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">17</xref>
Previous studies have assessed interaction between HLA and INS and reported divergent results [10-18]. The reported results of the joint effect of HLA and INS are confusing not only because they have shown diverging results but also because the definitions and terminology of interactions are not consistent [19]. The interpretation of statistical interaction depends on the choice of scale used to measure the effects [2]. Although additivity of risks is often taken as independence [20], multiplicativity of risk is sometimes also taken as independence [21]. The joint action of HLA and INS has variously been described as being multiplicative [14, 15], additive [13], providing evidence of interaction [15], and non-interacting [13, 14, 17].
###end p 16
###begin p 17
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 91 96 91 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 248 250 248 250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 252 254 252 254 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">23</xref>
###xml 305 307 305 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">24</xref>
###xml 308 310 308 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
Few studies have investigated the more recently established susceptibility loci PTPN22 and CTLA4 in the context of joint effects on the risk of type 1 diabetes. The studies that have been done have mainly concluded that there is a non-interaction [22, 23] effect, but here also the results have diverged [24-27].
###end p 17
###begin p 18
###xml 102 105 102 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 107 112 107 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 117 123 117 123 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
The aim of our study was to assess the joint effects of the four established susceptibility loci HLA, INS, CTLA4 and PTPN22 in type 1 diabetes, using a consistent approach with both population-based case-control and family trio designs and with large sample sizes.
###end p 18
###begin title 19
Methods
###end title 19
###begin p 20
###xml 0 12 0 12 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Participants</bold>
###xml 920 922 918 920 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">28</xref>
###xml 1066 1068 1064 1066 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">29</xref>
###xml 1339 1341 1337 1339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">30</xref>
###xml 0 12 <span type="species:ncbi:9606">Participants</span>
###xml 142 147 <span type="species:ncbi:9606">child</span>
###xml 238 246 <span type="species:ncbi:9606">children</span>
###xml 252 256 <span type="species:ncbi:9606">boys</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 483 487 <span type="species:ncbi:9606">boys</span>
###xml 498 503 <span type="species:ncbi:9606">girls</span>
###xml 522 526 <span type="species:ncbi:9606">boys</span>
###xml 537 542 <span type="species:ncbi:9606">girls</span>
###xml 552 564 <span type="species:ncbi:9606">participants</span>
###xml 700 705 <span type="species:ncbi:9606">child</span>
###xml 836 844 <span type="species:ncbi:9606">children</span>
###xml 929 937 <span type="species:ncbi:9606">patients</span>
###xml 1117 1125 <span type="species:ncbi:9606">patients</span>
###xml 1283 1291 <span type="species:ncbi:9606">patients</span>
###xml 1441 1453 <span type="species:ncbi:9606">participants</span>
Participants We analysed two independent type 1 diabetes data sets. One nuclear family set consisted of 421 trios with mother, father and one child diagnosed in Norway with type 1 diabetes before age 15 years (225 [53.4%] of the affected children were boys). The families were collected between 1993 and 1997. In families with more than one affected sibling, only the proband was included in the analyses. The case-control data set consisted of 1,331 type 1 diabetes patients (51.9% boys and 48.1% girls) and 1,625 (51.4% boys and 48.6% girls) control participants aged <15 years. In analyses involving age of disease onset, we divided the data sets according to age of disease onset of the affected child into three groups (0-4.9, 5-9.9 and >/=10 years). The controls were randomly selected from the official population registry among children born between 1985 and 1999 and recruited in 2001, as previously described [28]. The patients in the case-control material were from the Norwegian Childhood Diabetes Registry consecutively recruited between 1997 and 2000 [29] and between 2002 and 2005. The type 1 diabetes patients and their family members were recruited by the Norwegian Childhood Diabetes Study Group, including all paediatric departments in Norway. All type 1 diabetes patients were diagnosed according to EURODIAB criteria [30]. The study was approved by the local ethics committee, and informed consent was obtained from all participants or their parents.
###end p 20
###begin p 21
###xml 0 37 0 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Genomic DNA extraction and genotyping</bold>
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">31</xref>
###xml 260 268 260 268 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DRB1</italic>
###xml 270 275 270 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;DQA1</italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">32</xref>
###xml 439 441 439 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">33</xref>
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">34</xref>
###xml 623 627 623 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 629 633 629 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1</italic>
###xml 638 642 638 642 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1</italic>
###xml 664 671 664 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04</italic>
###xml 699 726 699 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04-DQA1*0301-DQB1*0302</italic>
###xml 752 761 752 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 766 770 766 770 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0404</italic>
###xml 810 812 810 812 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">35</xref>
###xml 879 888 879 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*04XX</italic>
###xml 952 960 952 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-VNTR</italic>
###xml 984 992 984 992 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;23&#160;HphI</italic>
###xml 1024 1028 1024 1028 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HphI</italic>
###xml 1057 1066 1057 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-VNTR.</italic>
###xml 1072 1079 1072 1079 <italic xmlns:xlink="http://www.w3.org/1999/xlink">23&#160;HphI</italic>
###xml 1108 1112 1108 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VNTR</italic>
###xml 1129 1137 1129 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">&#8722;23&#160;HphI</italic>
###xml 1165 1169 1165 1169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">VNTR</italic>
###xml 1184 1190 1184 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 1245 1254 1245 1254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg620Trp</italic>
###xml 1276 1282 1276 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
###xml 1313 1318 1313 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 1548 1549 1548 1549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM1">1</xref>
Genomic DNA extraction and genotyping In the majority of the type 1 diabetes case-control samples we used DNA extracted from buccal cells [31]. In all remaining samples, DNA was extracted from peripheral whole blood using a salting-out protocol. Genotyping of HLA-DRB1, -DQA1 and -DQB1 was performed using PCR-SSOP (sequence-specific oligonucleotide probing) mainly following published methods [32], or PCR-SSP (sequence-specific primer) [33, 34], or using time-resolved fluorescence technology in the Delfia assay (Perkin-Elmer Life Sciences, Turku, Finland). HLA genotypes were grouped into four risk categories based on DQB1, DQA1 and DRB1 genotypes, including DRB1*04 subtyping. The majority of DRB1*04-DQA1*0301-DQB1*0302 haplotypes in Norway are DRB1*0401 or -0404 (constituting >94% of the haplotypes) [35]. In the present study the other rare subtypes are referred to as DRB1*04XX. Because of the almost complete linkage disequilibrium between INS-VNTR allele classes and the -23 HphI polymorphism, we genotyped -23 HphI (rs689) as a marker for the INS-VNTR. The -23 HphI A allele corresponds to the VNTR class I and the -23 HphI T allele correspond to the VNTR class III. In PTPN22 we genotyped the single nucleotide polymorphism (SNP) Arg620Trp (rs2476601). The SNP JO27_1 (rs11571297) was genotyped in CTLA4. SNP genotyping was performed by TaqMan allelic discrimination assays on an ABI 7900HT DNA Analyzer (Applied Biosystems, Foster City, CA USA). Primer and probe sequences are shown in Electronic Supplementary Material (ESM) Table 1. The PCR conditions are available on request.
###end p 21
###begin p 22
###xml 0 13 0 13 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Data analysis</bold>
###xml 162 176 162 176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401/04XX</italic>
###xml 177 220 177 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*0201</italic>
###xml 222 225 222 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4</italic>
###xml 226 237 226 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQ8/DR3-DQ2</italic>
###xml 291 295 291 295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 337 358 337 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0404-DQ8/DR3-DQ2</italic>
###xml 360 375 360 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3-DQ2/DR3-DQ2</italic>
###xml 377 392 377 392 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4-DQ8/DR4-DQ8</italic>
###xml 416 429 416 429 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 0404-DQ8</italic>
###xml 475 484 475 484 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 488 499 488 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">040XX-DQ8/X</italic>
###xml 511 515 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1</italic>
###xml 516 520 508 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">0602</italic>
###xml 524 531 516 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3-DQ2</italic>
###xml 668 671 660 663 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 673 679 665 671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 684 689 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 702 705 694 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 788 794 780 786 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 838 843 830 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 845 851 837 843 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
###xml 2031 2033 2023 2025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR36">36</xref>
###xml 2682 2684 2674 2676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR37">37</xref>
###xml 2781 2783 2773 2775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR38">38</xref>
###xml 3515 3516 3507 3508 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
Data analysis The HLA haplotypes were grouped as high risk, intermediate risk, neutral risk and low risk according to the following criteria: high-risk category, DRB1*0401/04XX-DQA1*03-DQB1*0302/DRB1*03-DQA1*05-DQB1*0201 (DR4-DQ8/DR3-DQ2); low-risk category, all genotypes with at least one DQB1*0602 allele; intermediate-risk category, DRB1*0404-DQ8/DR3-DQ2, DR3-DQ2/DR3-DQ2, DR4-DQ8/DR4-DQ8 (with the exception of DRB1 0404-DQ8 homozygotes, which were grouped as neutral), DRB1*0401 or 040XX-DQ8/X (Xnot equalDQB1*0602 or DR3-DQ2). The remaining haplotypes were grouped in the neutral-risk category. For assessment of two-locus joint effects, we pooled genotypes of INS, PTPN22 and CTLA4 as follows: INS class I/I genotypes were compared with I/III together with III/III genotypes. The PTPN22 TT and CT genotypes were compared with CC. CTLA4 (JO27_1) TT genotypes were compared with TC and CC genotypes. Not all individuals were genotyped for non-HLA polymorphisms because of lack of DNA. We did not exclude individuals with some missing genotypes to prevent the loss of important information when looking at joint effects between polymorphisms. The available numbers of individuals for each analysis are seen in the tables. Data were presented using stratified 2 x 2 tables and analysed using logistic regression models including interaction (product) terms, in SPSS for Windows (version 14.0; SPSS, Chicago, IL, USA). In addition to formal analyses treating HLA categories as categorical in the logistic regression, we also tested for interactions when treating HLA category as a continuous variable coded 1, 2, 3, 4, thus maximising the power under alternative models where the effect of a non-HLA locus (as measured by the odds ratio [OR]) was assumed to decrease (or increase) (logit) linearly over the four HLA risk categories (test for interaction with one degree of freedom). Case-only analyses were used to estimate interaction parameters and to test for deviation from multiplicative effects using logistic regression [36]. In addition to the increased power obtained by utilising all cases (from case-control and trio materials) simultaneously, case-only analyses have increased power by making the implicit assumption that there is no association between the two loci in the population; i.e. the OR for their association is 1.0 in the population. Thus, under reasonable assumptions the case-only analysis makes the most efficient use of data to assess deviation from multiplicative models. In the case-control analysis, likelihood ratio tests comparing nested logistic regression models were used as global tests for interaction. The transmission disequilibrium test [37] was performed using the UNPHASED application implemented in the UNPHASED software version 2.4 [38]. For the trio data, 95% confidence intervals for the relative risk were estimated using conditional logistic regression in UNPHASED. Receiver operating curve (ROC) and confidence bounds for the area under the curve were estimated assuming a non-parametric distribution and analyses were done using SPSS version 14.0. Genotypes were added sequentially in order of likelihood ratio (or equivalently by the absolute risk conferred by a given genotype combination estimated using Bayes' formula). Two four-locus genotype combinations were absent among cases in our material, and a very low value for the estimated absolute risk was imputed for these to allow inclusion in the ROC curve estimation with all four loci simultaneously. A p value <0.05 was considered to be statistically significant.
###end p 22
###begin title 23
Results
###end title 23
###begin p 24
###xml 53 54 53 54 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM2">2</xref>
###xml 89 90 89 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM3">3</xref>
###xml 325 328 325 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 330 336 330 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 515 520 515 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 522 528 522 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
###xml 573 579 573 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM3">3</xref>
The single-locus main effects are shown in ESM Table 2 (case-control data) and ESM Table 3 (trios). Compared with the neutral HLA risk category, the high-risk category showed a strong association with type 1 diabetes, with OR 20.6; for the intermediate-risk category the OR was 5.7 and for the low-risk category it was 0.09. INS, PTPN22 and CTLA4 also showed an association with type 1 diabetes, as expected. The transmission of the risk allele in the nuclear families confirmed the associations in INS, PTPN22 and CTLA4 (JO27_1), although with borderline significance for JO27_1 (ESM Table 3).
###end p 24
###begin p 25
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Joint effect of HLA and PTPN22</bold>
###xml 53 59 53 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 301 303 301 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 321 327 321 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 398 400 398 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 463 469 463 469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 597 598 597 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM4">4</xref>
###xml 692 693 692 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM5">5</xref>
###xml 796 802 796 802 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 833 835 833 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 858 860 858 860 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 945 947 945 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 1007 1009 1007 1009 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 1060 1066 1060 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 1089 1091 1089 1091 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 1098 1100 1098 1100 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 1253 1255 1253 1255 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR39">39</xref>
Joint effect of HLA and PTPN22 ORs for the effect of PTPN22 varied across the HLA risk categories and were significant in some of the subgroups. The ORs were smaller for the risk-conferring HLA genotypes, indicating negative deviation from a multiplicative model. A global test of interaction (with 3 df) between HLA and PTPN22 in the logistic regression model confirmed a significant interaction (p = 0.024). In the trio data, the relative risk conferred by the PTPN22 T allele was similar in the strata defined by HLA group, with no evidence for deviation from a multiplicative model (ESM Table 4). A case-only analysis among all cases from the case-control and family materials (ESM Table 5) supported a significant negative deviation from multiplicative effects, with weaker ORs conferred by PTPN22 in the HLA risk categories (3 df test for interaction; p = 0.028). When treating HLA-encoded risk as a continuous variable in the analysis (1 df), the interaction was even more statistically significant (p = 0.003). There was no association between HLA and PTPN22 among the controls (3 df test; p = 0.19). We tried to fit the case-control data to an additive odds model using generalised linear models in STATA (version 9), as described by Skrondal [39]. However, convergence was not obtained, suggesting that the data did not fit well to an additive model.
###end p 25
###begin p 26
###xml 0 27 0 27 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Joint effect of HLA and INS</bold>
###xml 34 36 34 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 66 69 66 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 113 115 113 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 246 248 246 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM4">4</xref>
###xml 301 303 301 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 310 312 310 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM5">5</xref>
###xml 441 443 441 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 450 452 450 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 499 502 499 502 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 542 544 542 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 551 553 551 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
Joint effect of HLA and INS The 3 df test for interaction between INS and HLA was not statistically significant (p = 0.67). There was also no statistically significant deviation from a multiplicative model in the trio data (test for interaction, p = 0.5) (ESM Table 4) or in the case-only analysis (3 df test; p = 0.49) (ESM Table 5); even when treating HLA-encoded risk as a continuous variable in the analysis there was no significance (1 df test, p = 0.12). There was also no association between INS and HLA among controls, as expected (3 df test; p = 0.41).
###end p 26
###begin p 27
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Joint effect of HLA and CTLA4</bold>
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 87 88 87 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 154 156 154 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 163 165 163 165 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 229 230 229 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM4">4</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM5">5</xref>
###xml 292 294 292 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 301 303 301 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">df</italic>
###xml 392 394 392 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 403 410 403 410 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 430 437 430 437 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-INS</italic>
###xml 439 446 439 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-23HphI</italic>
###xml 449 459 449 459 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-PTPN22</italic>
###xml 461 470 461 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg620Trp</italic>
###xml 476 485 476 485 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-CTLA4</italic>
###xml 487 493 487 493 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
###xml 410 549 410 549 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="28">Interaction between <italic>HLA-INS</italic> (<italic>-23HphI</italic>), <italic>HLA-PTPN22</italic> (<italic>Arg620Trp</italic>) and <italic>HLA-CTLA4</italic> (<italic>JO27_1</italic>) in the case&#8211;control data set using logistic regression</p>
###xml 410 549 410 549 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="28">Interaction between <italic>HLA-INS</italic> (<italic>-23HphI</italic>), <italic>HLA-PTPN22</italic> (<italic>Arg620Trp</italic>) and <italic>HLA-CTLA4</italic> (<italic>JO27_1</italic>) in the case&#8211;control data set using logistic regression</p></caption>
###xml 561 562 561 562 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 549 562 549 562 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">HLA category<sup>a</sup></th>
###xml 562 579 562 579 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Non-HLA genotypes</th>
###xml 579 584 579 584 <th xmlns:xlink="http://www.w3.org/1999/xlink">Cases</th>
###xml 584 592 584 592 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls</th>
###xml 592 594 592 594 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">OR</th>
###xml 594 600 594 600 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">95% CI</th>
###xml 622 623 622 623 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 600 630 600 630 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Test for interaction (<italic>p</italic> value)</th>
###xml 549 630 549 630 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2">HLA category<sup>a</sup></th><th rowspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction (<italic>p</italic> value)</th></tr>
###xml 630 631 630 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 630 635 630 635 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic> (%)</th>
###xml 635 636 635 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 638 639 638 639 <italic xmlns:xlink="http://www.w3.org/1999/xlink">%</italic>
###xml 635 640 635 640 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic> (<italic>%</italic>)</th>
###xml 630 640 630 640 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th><italic>n</italic> (%)</th><th><italic>n</italic> (<italic>%</italic>)</th></tr>
###xml 549 640 549 640 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2">HLA category<sup>a</sup></th><th rowspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (<italic>%</italic>)</th></tr></thead>
###xml 640 640 640 640 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 640 643 640 643 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 643 644 643 644 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 640 644 640 644 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INS</italic><sup>b</sup></td>
###xml 644 644 644 644 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 644 644 644 644 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 644 644 644 644 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 644 644 644 644 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 644 648 644 648 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.67</td>
###xml 640 648 640 648 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td><italic>INS</italic><sup>b</sup></td><td/><td/><td/><td/><td>0.67</td></tr>
###xml 648 657 648 657 <td xmlns:xlink="http://www.w3.org/1999/xlink">High risk</td>
###xml 657 660 657 660 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 660 670 660 670 <td xmlns:xlink="http://www.w3.org/1999/xlink">218 (25.2)</td>
###xml 670 678 670 678 <td xmlns:xlink="http://www.w3.org/1999/xlink">20 (2.8)</td>
###xml 678 682 678 682 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.56</td>
###xml 682 691 682 691 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.76&#8211;3.21</td>
###xml 691 691 691 691 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 648 691 648 691 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>High risk</td><td>I-I</td><td>218 (25.2)</td><td>20 (2.8)</td><td>1.56</td><td>0.76&#8211;3.21</td><td/></tr>
###xml 691 691 691 691 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 691 695 691 695 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 695 704 695 704 <td xmlns:xlink="http://www.w3.org/1999/xlink">98 (28.6)</td>
###xml 704 712 704 712 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (2.5)</td>
###xml 712 713 712 713 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 713 713 713 713 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 713 713 713 713 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 691 713 691 713 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>III+</td><td>98 (28.6)</td><td>14 (2.5)</td><td>1</td><td/><td/></tr>
###xml 713 730 713 730 <td xmlns:xlink="http://www.w3.org/1999/xlink">Intermediate risk</td>
###xml 730 733 730 733 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 733 743 733 743 <td xmlns:xlink="http://www.w3.org/1999/xlink">412 (47.6)</td>
###xml 743 753 743 753 <td xmlns:xlink="http://www.w3.org/1999/xlink">122 (17.1)</td>
###xml 753 757 753 757 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.10</td>
###xml 757 766 757 766 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.52&#8211;2.89</td>
###xml 766 766 766 766 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 713 766 713 766 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Intermediate risk</td><td>I-I</td><td>412 (47.6)</td><td>122 (17.1)</td><td>2.10</td><td>1.52&#8211;2.89</td><td/></tr>
###xml 766 766 766 766 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 766 770 766 770 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 770 780 770 780 <td xmlns:xlink="http://www.w3.org/1999/xlink">160 (46.8)</td>
###xml 780 789 780 789 <td xmlns:xlink="http://www.w3.org/1999/xlink">99 (17.4)</td>
###xml 789 790 789 790 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 790 790 790 790 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 790 790 790 790 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 766 790 766 790 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>III+</td><td>160 (46.8)</td><td>99 (17.4)</td><td>1</td><td/><td/></tr>
###xml 790 802 790 802 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neutral risk</td>
###xml 802 805 802 805 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 805 815 805 815 <td xmlns:xlink="http://www.w3.org/1999/xlink">221 (25.5)</td>
###xml 815 825 815 825 <td xmlns:xlink="http://www.w3.org/1999/xlink">346 (48.5)</td>
###xml 825 829 825 829 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.34</td>
###xml 829 838 829 838 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.74&#8211;3.15</td>
###xml 838 838 838 838 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 790 838 790 838 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Neutral risk</td><td>I-I</td><td>221 (25.5)</td><td>346 (48.5)</td><td>2.34</td><td>1.74&#8211;3.15</td><td/></tr>
###xml 838 838 838 838 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 838 842 838 842 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 842 851 842 851 <td xmlns:xlink="http://www.w3.org/1999/xlink">81 (23.7)</td>
###xml 851 861 851 861 <td xmlns:xlink="http://www.w3.org/1999/xlink">299 (52.6)</td>
###xml 861 862 861 862 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 862 862 862 862 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 862 862 862 862 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 838 862 838 862 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>III+</td><td>81 (23.7)</td><td>299 (52.6)</td><td>1</td><td/><td/></tr>
###xml 862 870 862 870 <td xmlns:xlink="http://www.w3.org/1999/xlink">Low risk</td>
###xml 870 873 870 873 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 873 881 873 881 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (1.6)</td>
###xml 881 891 881 891 <td xmlns:xlink="http://www.w3.org/1999/xlink">225 (31.6)</td>
###xml 891 895 891 895 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.26</td>
###xml 895 905 895 905 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.92&#8211;11.54</td>
###xml 905 905 905 905 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 862 905 862 905 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Low risk</td><td>I-I</td><td>14 (1.6)</td><td>225 (31.6)</td><td>3.26</td><td>0.92&#8211;11.54</td><td/></tr>
###xml 905 905 905 905 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 905 909 905 909 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 909 916 909 916 <td xmlns:xlink="http://www.w3.org/1999/xlink">3 (0.9)</td>
###xml 916 926 916 926 <td xmlns:xlink="http://www.w3.org/1999/xlink">156 (27.5)</td>
###xml 926 927 926 927 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 927 927 927 927 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 927 927 927 927 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 905 927 905 927 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>III+</td><td>3 (0.9)</td><td>156 (27.5)</td><td>1</td><td/><td/></tr>
###xml 927 932 927 932 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total</td>
###xml 932 932 932 932 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 932 936 932 936 <td xmlns:xlink="http://www.w3.org/1999/xlink">1207</td>
###xml 936 940 936 940 <td xmlns:xlink="http://www.w3.org/1999/xlink">1281</td>
###xml 940 940 940 940 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 940 940 940 940 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 940 940 940 940 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 927 940 927 940 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total</td><td/><td>1207</td><td>1281</td><td/><td/><td/></tr>
###xml 940 940 940 940 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 940 946 940 946 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 940 946 940 946 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PTPN22</italic></td>
###xml 946 946 946 946 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 946 946 946 946 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 946 946 946 946 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 946 946 946 946 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 946 951 946 951 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.024</td>
###xml 940 951 940 951 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td><italic>PTPN22</italic></td><td/><td/><td/><td/><td>0.024</td></tr>
###xml 951 960 951 960 <td xmlns:xlink="http://www.w3.org/1999/xlink">High risk</td>
###xml 960 967 960 967 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT&#8201;+&#8201;TC</td>
###xml 967 976 967 976 <td xmlns:xlink="http://www.w3.org/1999/xlink">89 (23.2)</td>
###xml 976 983 976 983 <td xmlns:xlink="http://www.w3.org/1999/xlink">8 (3.1)</td>
###xml 983 987 983 987 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.26</td>
###xml 987 996 987 996 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.55&#8211;2.88</td>
###xml 996 996 996 996 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 951 996 951 996 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>High risk</td><td>TT&#8201;+&#8201;TC</td><td>89 (23.2)</td><td>8 (3.1)</td><td>1.26</td><td>0.55&#8211;2.88</td><td/></tr>
###xml 996 996 996 996 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 996 998 996 998 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 998 1008 998 1008 <td xmlns:xlink="http://www.w3.org/1999/xlink">237 (27.8)</td>
###xml 1008 1016 1008 1016 <td xmlns:xlink="http://www.w3.org/1999/xlink">27 (2.6)</td>
###xml 1016 1017 1016 1017 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1017 1017 1017 1017 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1017 1017 1017 1017 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 996 1017 996 1017 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>CC</td><td>237 (27.8)</td><td>27 (2.6)</td><td>1</td><td/><td/></tr>
###xml 1017 1034 1017 1034 <td xmlns:xlink="http://www.w3.org/1999/xlink">Intermediate risk</td>
###xml 1034 1041 1034 1041 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT&#8201;+&#8201;TC</td>
###xml 1041 1051 1041 1051 <td xmlns:xlink="http://www.w3.org/1999/xlink">177 (46.1)</td>
###xml 1051 1060 1051 1060 <td xmlns:xlink="http://www.w3.org/1999/xlink">55 (21.2)</td>
###xml 1060 1064 1060 1064 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.31</td>
###xml 1064 1073 1064 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.91&#8211;1.86</td>
###xml 1073 1073 1073 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1017 1073 1017 1073 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Intermediate risk</td><td>TT&#8201;+&#8201;TC</td><td>177 (46.1)</td><td>55 (21.2)</td><td>1.31</td><td>0.91&#8211;1.86</td><td/></tr>
###xml 1073 1073 1073 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1073 1075 1073 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 1075 1085 1075 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink">406 (47.7)</td>
###xml 1085 1095 1085 1095 <td xmlns:xlink="http://www.w3.org/1999/xlink">164 (15.6)</td>
###xml 1095 1096 1095 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1096 1096 1096 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1096 1096 1096 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1073 1096 1073 1096 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>CC</td><td>406 (47.7)</td><td>164 (15.6)</td><td>1</td><td/><td/></tr>
###xml 1096 1108 1096 1108 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neutral risk</td>
###xml 1108 1115 1108 1115 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT&#8201;+&#8201;TC</td>
###xml 1115 1125 1115 1125 <td xmlns:xlink="http://www.w3.org/1999/xlink">111 (28.9)</td>
###xml 1125 1135 1125 1135 <td xmlns:xlink="http://www.w3.org/1999/xlink">121 (46.7)</td>
###xml 1135 1139 1135 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink">2.44</td>
###xml 1139 1148 1139 1148 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.80&#8211;3.31</td>
###xml 1148 1148 1148 1148 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1096 1148 1096 1148 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Neutral risk</td><td>TT&#8201;+&#8201;TC</td><td>111 (28.9)</td><td>121 (46.7)</td><td>2.44</td><td>1.80&#8211;3.31</td><td/></tr>
###xml 1148 1148 1148 1148 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1148 1150 1148 1150 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 1150 1160 1150 1160 <td xmlns:xlink="http://www.w3.org/1999/xlink">199 (23.4)</td>
###xml 1160 1170 1160 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink">536 (51.0)</td>
###xml 1170 1171 1170 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1171 1171 1171 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1171 1171 1171 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1148 1171 1148 1171 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>CC</td><td>199 (23.4)</td><td>536 (51.0)</td><td>1</td><td/><td/></tr>
###xml 1171 1179 1171 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink">Low risk</td>
###xml 1179 1186 1179 1186 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT&#8201;+&#8201;TC</td>
###xml 1186 1193 1186 1193 <td xmlns:xlink="http://www.w3.org/1999/xlink">7 (1.8)</td>
###xml 1193 1202 1193 1202 <td xmlns:xlink="http://www.w3.org/1999/xlink">75 (29.0)</td>
###xml 1202 1206 1202 1206 <td xmlns:xlink="http://www.w3.org/1999/xlink">3.27</td>
###xml 1206 1215 1206 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.18&#8211;9.06</td>
###xml 1215 1215 1215 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1171 1215 1171 1215 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Low risk</td><td>TT&#8201;+&#8201;TC</td><td>7 (1.8)</td><td>75 (29.0)</td><td>3.27</td><td>1.18&#8211;9.06</td><td/></tr>
###xml 1215 1215 1215 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1215 1217 1215 1217 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 1217 1224 1217 1224 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (1.1)</td>
###xml 1224 1234 1224 1234 <td xmlns:xlink="http://www.w3.org/1999/xlink">323 (30.8)</td>
###xml 1234 1235 1234 1235 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1235 1235 1235 1235 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1235 1235 1235 1235 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1215 1235 1215 1235 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>CC</td><td>9 (1.1)</td><td>323 (30.8)</td><td>1</td><td/><td/></tr>
###xml 1235 1240 1235 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total</td>
###xml 1240 1240 1240 1240 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1240 1244 1240 1244 <td xmlns:xlink="http://www.w3.org/1999/xlink">1235</td>
###xml 1244 1248 1244 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink">1309</td>
###xml 1248 1248 1248 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1248 1248 1248 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1248 1248 1248 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1235 1248 1235 1248 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total</td><td/><td>1235</td><td>1309</td><td/><td/><td/></tr>
###xml 1248 1248 1248 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1248 1253 1248 1253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 1248 1253 1248 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>CTLA4</italic></td>
###xml 1253 1253 1253 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1253 1253 1253 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1253 1253 1253 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1253 1253 1253 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1253 1257 1253 1257 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.53</td>
###xml 1248 1257 1248 1257 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td><italic>CTLA4</italic></td><td/><td/><td/><td/><td>0.53</td></tr>
###xml 1257 1266 1257 1266 <td xmlns:xlink="http://www.w3.org/1999/xlink">High risk</td>
###xml 1266 1268 1266 1268 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 1268 1278 1268 1278 <td xmlns:xlink="http://www.w3.org/1999/xlink">122 (24.9)</td>
###xml 1278 1286 1278 1286 <td xmlns:xlink="http://www.w3.org/1999/xlink">14 (3.6)</td>
###xml 1286 1290 1286 1290 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.90</td>
###xml 1290 1299 1290 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.45&#8211;1.84</td>
###xml 1299 1299 1299 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1257 1299 1257 1299 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>High risk</td><td>TT</td><td>122 (24.9)</td><td>14 (3.6)</td><td>0.90</td><td>0.45&#8211;1.84</td><td/></tr>
###xml 1299 1299 1299 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1299 1304 1299 1304 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1304 1314 1304 1314 <td xmlns:xlink="http://www.w3.org/1999/xlink">210 (27.9)</td>
###xml 1314 1322 1314 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink">22 (2.5)</td>
###xml 1322 1323 1322 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1323 1323 1323 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1323 1323 1323 1323 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1299 1323 1299 1323 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>TC-CC</td><td>210 (27.9)</td><td>22 (2.5)</td><td>1</td><td/><td/></tr>
###xml 1323 1340 1323 1340 <td xmlns:xlink="http://www.w3.org/1999/xlink">Intermediate risk</td>
###xml 1340 1342 1340 1342 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 1342 1352 1342 1352 <td xmlns:xlink="http://www.w3.org/1999/xlink">241 (49.2)</td>
###xml 1352 1361 1352 1361 <td xmlns:xlink="http://www.w3.org/1999/xlink">65 (16.5)</td>
###xml 1361 1365 1361 1365 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.59</td>
###xml 1365 1374 1365 1374 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.14&#8211;2.23</td>
###xml 1374 1374 1374 1374 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1323 1374 1323 1374 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Intermediate risk</td><td>TT</td><td>241 (49.2)</td><td>65 (16.5)</td><td>1.59</td><td>1.14&#8211;2.23</td><td/></tr>
###xml 1374 1374 1374 1374 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1374 1379 1374 1379 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1379 1389 1379 1389 <td xmlns:xlink="http://www.w3.org/1999/xlink">346 (46.0)</td>
###xml 1389 1399 1389 1399 <td xmlns:xlink="http://www.w3.org/1999/xlink">148 (16.7)</td>
###xml 1399 1400 1399 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1400 1400 1400 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1400 1400 1400 1400 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1374 1400 1374 1400 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>TC-CC</td><td>346 (46.0)</td><td>148 (16.7)</td><td>1</td><td/><td/></tr>
###xml 1400 1412 1400 1412 <td xmlns:xlink="http://www.w3.org/1999/xlink">Neutral risk</td>
###xml 1412 1414 1412 1414 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 1414 1424 1414 1424 <td xmlns:xlink="http://www.w3.org/1999/xlink">121 (24.7)</td>
###xml 1424 1434 1424 1434 <td xmlns:xlink="http://www.w3.org/1999/xlink">212 (53.8)</td>
###xml 1434 1438 1434 1438 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.34</td>
###xml 1438 1447 1438 1447 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.01&#8211;1.77</td>
###xml 1447 1447 1447 1447 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1400 1447 1400 1447 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Neutral risk</td><td>TT</td><td>121 (24.7)</td><td>212 (53.8)</td><td>1.34</td><td>1.01&#8211;1.77</td><td/></tr>
###xml 1447 1447 1447 1447 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1447 1452 1447 1452 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1452 1462 1452 1462 <td xmlns:xlink="http://www.w3.org/1999/xlink">187 (24.9)</td>
###xml 1462 1472 1462 1472 <td xmlns:xlink="http://www.w3.org/1999/xlink">439 (49.7)</td>
###xml 1472 1473 1472 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1473 1473 1473 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1473 1473 1473 1473 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1447 1473 1447 1473 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>TC-CC</td><td>187 (24.9)</td><td>439 (49.7)</td><td>1</td><td/><td/></tr>
###xml 1473 1481 1473 1481 <td xmlns:xlink="http://www.w3.org/1999/xlink">Low risk</td>
###xml 1481 1483 1481 1483 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 1483 1490 1483 1490 <td xmlns:xlink="http://www.w3.org/1999/xlink">6 (1.2)</td>
###xml 1490 1500 1490 1500 <td xmlns:xlink="http://www.w3.org/1999/xlink">103 (26.1)</td>
###xml 1500 1504 1500 1504 <td xmlns:xlink="http://www.w3.org/1999/xlink">1.80</td>
###xml 1504 1513 1504 1513 <td xmlns:xlink="http://www.w3.org/1999/xlink">0.63&#8211;5.18</td>
###xml 1513 1513 1513 1513 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1473 1513 1473 1513 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Low risk</td><td>TT</td><td>6 (1.2)</td><td>103 (26.1)</td><td>1.80</td><td>0.63&#8211;5.18</td><td/></tr>
###xml 1513 1513 1513 1513 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1513 1518 1513 1518 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1518 1525 1518 1525 <td xmlns:xlink="http://www.w3.org/1999/xlink">9 (1.2)</td>
###xml 1525 1535 1525 1535 <td xmlns:xlink="http://www.w3.org/1999/xlink">275 (31.1)</td>
###xml 1535 1536 1535 1536 <td xmlns:xlink="http://www.w3.org/1999/xlink">1</td>
###xml 1536 1536 1536 1536 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1536 1536 1536 1536 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1513 1536 1513 1536 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td/><td>TC-CC</td><td>9 (1.2)</td><td>275 (31.1)</td><td>1</td><td/><td/></tr>
###xml 1536 1541 1536 1541 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total</td>
###xml 1541 1541 1541 1541 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1541 1545 1541 1545 <td xmlns:xlink="http://www.w3.org/1999/xlink">1242</td>
###xml 1545 1549 1545 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink">1278</td>
###xml 1549 1549 1549 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1549 1549 1549 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1549 1549 1549 1549 <td xmlns:xlink="http://www.w3.org/1999/xlink"/>
###xml 1536 1549 1536 1549 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total</td><td/><td>1242</td><td>1278</td><td/><td/><td/></tr>
###xml 640 1549 640 1549 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td/><td><italic>INS</italic><sup>b</sup></td><td/><td/><td/><td/><td>0.67</td></tr><tr><td>High risk</td><td>I-I</td><td>218 (25.2)</td><td>20 (2.8)</td><td>1.56</td><td>0.76&#8211;3.21</td><td/></tr><tr><td/><td>III+</td><td>98 (28.6)</td><td>14 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>I-I</td><td>412 (47.6)</td><td>122 (17.1)</td><td>2.10</td><td>1.52&#8211;2.89</td><td/></tr><tr><td/><td>III+</td><td>160 (46.8)</td><td>99 (17.4)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>I-I</td><td>221 (25.5)</td><td>346 (48.5)</td><td>2.34</td><td>1.74&#8211;3.15</td><td/></tr><tr><td/><td>III+</td><td>81 (23.7)</td><td>299 (52.6)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>I-I</td><td>14 (1.6)</td><td>225 (31.6)</td><td>3.26</td><td>0.92&#8211;11.54</td><td/></tr><tr><td/><td>III+</td><td>3 (0.9)</td><td>156 (27.5)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1207</td><td>1281</td><td/><td/><td/></tr><tr><td/><td><italic>PTPN22</italic></td><td/><td/><td/><td/><td>0.024</td></tr><tr><td>High risk</td><td>TT&#8201;+&#8201;TC</td><td>89 (23.2)</td><td>8 (3.1)</td><td>1.26</td><td>0.55&#8211;2.88</td><td/></tr><tr><td/><td>CC</td><td>237 (27.8)</td><td>27 (2.6)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT&#8201;+&#8201;TC</td><td>177 (46.1)</td><td>55 (21.2)</td><td>1.31</td><td>0.91&#8211;1.86</td><td/></tr><tr><td/><td>CC</td><td>406 (47.7)</td><td>164 (15.6)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT&#8201;+&#8201;TC</td><td>111 (28.9)</td><td>121 (46.7)</td><td>2.44</td><td>1.80&#8211;3.31</td><td/></tr><tr><td/><td>CC</td><td>199 (23.4)</td><td>536 (51.0)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT&#8201;+&#8201;TC</td><td>7 (1.8)</td><td>75 (29.0)</td><td>3.27</td><td>1.18&#8211;9.06</td><td/></tr><tr><td/><td>CC</td><td>9 (1.1)</td><td>323 (30.8)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1235</td><td>1309</td><td/><td/><td/></tr><tr><td/><td><italic>CTLA4</italic></td><td/><td/><td/><td/><td>0.53</td></tr><tr><td>High risk</td><td>TT</td><td>122 (24.9)</td><td>14 (3.6)</td><td>0.90</td><td>0.45&#8211;1.84</td><td/></tr><tr><td/><td>TC-CC</td><td>210 (27.9)</td><td>22 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT</td><td>241 (49.2)</td><td>65 (16.5)</td><td>1.59</td><td>1.14&#8211;2.23</td><td/></tr><tr><td/><td>TC-CC</td><td>346 (46.0)</td><td>148 (16.7)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT</td><td>121 (24.7)</td><td>212 (53.8)</td><td>1.34</td><td>1.01&#8211;1.77</td><td/></tr><tr><td/><td>TC-CC</td><td>187 (24.9)</td><td>439 (49.7)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT</td><td>6 (1.2)</td><td>103 (26.1)</td><td>1.80</td><td>0.63&#8211;5.18</td><td/></tr><tr><td/><td>TC-CC</td><td>9 (1.2)</td><td>275 (31.1)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1242</td><td>1278</td><td/><td/><td/></tr></tbody>
###xml 549 1549 549 1549 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2">HLA category<sup>a</sup></th><th rowspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (<italic>%</italic>)</th></tr></thead><tbody><tr><td/><td><italic>INS</italic><sup>b</sup></td><td/><td/><td/><td/><td>0.67</td></tr><tr><td>High risk</td><td>I-I</td><td>218 (25.2)</td><td>20 (2.8)</td><td>1.56</td><td>0.76&#8211;3.21</td><td/></tr><tr><td/><td>III+</td><td>98 (28.6)</td><td>14 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>I-I</td><td>412 (47.6)</td><td>122 (17.1)</td><td>2.10</td><td>1.52&#8211;2.89</td><td/></tr><tr><td/><td>III+</td><td>160 (46.8)</td><td>99 (17.4)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>I-I</td><td>221 (25.5)</td><td>346 (48.5)</td><td>2.34</td><td>1.74&#8211;3.15</td><td/></tr><tr><td/><td>III+</td><td>81 (23.7)</td><td>299 (52.6)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>I-I</td><td>14 (1.6)</td><td>225 (31.6)</td><td>3.26</td><td>0.92&#8211;11.54</td><td/></tr><tr><td/><td>III+</td><td>3 (0.9)</td><td>156 (27.5)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1207</td><td>1281</td><td/><td/><td/></tr><tr><td/><td><italic>PTPN22</italic></td><td/><td/><td/><td/><td>0.024</td></tr><tr><td>High risk</td><td>TT&#8201;+&#8201;TC</td><td>89 (23.2)</td><td>8 (3.1)</td><td>1.26</td><td>0.55&#8211;2.88</td><td/></tr><tr><td/><td>CC</td><td>237 (27.8)</td><td>27 (2.6)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT&#8201;+&#8201;TC</td><td>177 (46.1)</td><td>55 (21.2)</td><td>1.31</td><td>0.91&#8211;1.86</td><td/></tr><tr><td/><td>CC</td><td>406 (47.7)</td><td>164 (15.6)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT&#8201;+&#8201;TC</td><td>111 (28.9)</td><td>121 (46.7)</td><td>2.44</td><td>1.80&#8211;3.31</td><td/></tr><tr><td/><td>CC</td><td>199 (23.4)</td><td>536 (51.0)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT&#8201;+&#8201;TC</td><td>7 (1.8)</td><td>75 (29.0)</td><td>3.27</td><td>1.18&#8211;9.06</td><td/></tr><tr><td/><td>CC</td><td>9 (1.1)</td><td>323 (30.8)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1235</td><td>1309</td><td/><td/><td/></tr><tr><td/><td><italic>CTLA4</italic></td><td/><td/><td/><td/><td>0.53</td></tr><tr><td>High risk</td><td>TT</td><td>122 (24.9)</td><td>14 (3.6)</td><td>0.90</td><td>0.45&#8211;1.84</td><td/></tr><tr><td/><td>TC-CC</td><td>210 (27.9)</td><td>22 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT</td><td>241 (49.2)</td><td>65 (16.5)</td><td>1.59</td><td>1.14&#8211;2.23</td><td/></tr><tr><td/><td>TC-CC</td><td>346 (46.0)</td><td>148 (16.7)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT</td><td>121 (24.7)</td><td>212 (53.8)</td><td>1.34</td><td>1.01&#8211;1.77</td><td/></tr><tr><td/><td>TC-CC</td><td>187 (24.9)</td><td>439 (49.7)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT</td><td>6 (1.2)</td><td>103 (26.1)</td><td>1.80</td><td>0.63&#8211;5.18</td><td/></tr><tr><td/><td>TC-CC</td><td>9 (1.2)</td><td>275 (31.1)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1242</td><td>1278</td><td/><td/><td/></tr></tbody></table>
###xml 1549 1550 1549 1550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1549 1576 1549 1576 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="29"><italic>n</italic>, Number of cases/controls</p>
###xml 1576 1577 1576 1577 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1609 1644 1609 1644 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1*03-DQB1*0302/DQA1*05-DQB1*0201</italic>
###xml 1646 1653 1646 1653 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQ8/DQ2</italic>
###xml 1662 1679 1662 1671 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1&#8800;0404</italic>
###xml 1704 1713 1696 1705 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1*0602</italic>
###xml 1785 1806 1777 1798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0404-DQ8/DR3-DQ2</italic>
###xml 1808 1823 1800 1815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3-DQ2/DR3-DQ2</italic>
###xml 1825 1840 1817 1832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4-DQ8/DR4-DQ8</italic>
###xml 1863 1872 1855 1864 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 0404</italic>
###xml 1875 1884 1867 1876 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 1888 1898 1880 1890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">040x-DQ8/X</italic>
###xml 1910 1919 1894 1903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1*0602</italic>
###xml 1923 1926 1907 1910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3</italic>
###xml 1576 2009 1576 1993 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30"><sup>a</sup>HLA risk categories: high risk, <italic>DQA1*03-DQB1*0302/DQA1*05-DQB1*0201</italic> (<italic>DQ8/DQ2</italic>), where <italic>DRB1&#8800;0404</italic>; low risk, at least one <italic>DQB1*0602</italic> allele independent of genotype on the other allele; intermediate risk, <italic>DRB1*0404-DQ8/DR3-DQ2</italic>, <italic>DR3-DQ2/DR3-DQ2</italic>, <italic>DR4-DQ8/DR4-DQ8</italic> (excluding homozygous <italic>DRB1 0404</italic>), <italic>DRB1*0401</italic> or <italic>040x-DQ8/X</italic> (X&#8800;<italic>DQB1*0602</italic> or <italic>DR3</italic>). The remaining haplotypes were grouped in the neutral risk category (see Methods)</p>
###xml 2009 2010 1993 1994 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 2009 2048 1993 2032 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="31"><sup>b</sup>Represents genotypes III/III and I/III</p>
###xml 1549 2048 1549 2032 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="29"><italic>n</italic>, Number of cases/controls</p><p textid="30"><sup>a</sup>HLA risk categories: high risk, <italic>DQA1*03-DQB1*0302/DQA1*05-DQB1*0201</italic> (<italic>DQ8/DQ2</italic>), where <italic>DRB1&#8800;0404</italic>; low risk, at least one <italic>DQB1*0602</italic> allele independent of genotype on the other allele; intermediate risk, <italic>DRB1*0404-DQ8/DR3-DQ2</italic>, <italic>DR3-DQ2/DR3-DQ2</italic>, <italic>DR4-DQ8/DR4-DQ8</italic> (excluding homozygous <italic>DRB1 0404</italic>), <italic>DRB1*0401</italic> or <italic>040x-DQ8/X</italic> (X&#8800;<italic>DQB1*0602</italic> or <italic>DR3</italic>). The remaining haplotypes were grouped in the neutral risk category (see Methods)</p><p textid="31"><sup>b</sup>Represents genotypes III/III and I/III</p></table-wrap-foot>
###xml 403 2048 403 2032 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="28">Interaction between <italic>HLA-INS</italic> (<italic>-23HphI</italic>), <italic>HLA-PTPN22</italic> (<italic>Arg620Trp</italic>) and <italic>HLA-CTLA4</italic> (<italic>JO27_1</italic>) in the case&#8211;control data set using logistic regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">HLA category<sup>a</sup></th><th rowspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (<italic>%</italic>)</th></tr></thead><tbody><tr><td/><td><italic>INS</italic><sup>b</sup></td><td/><td/><td/><td/><td>0.67</td></tr><tr><td>High risk</td><td>I-I</td><td>218 (25.2)</td><td>20 (2.8)</td><td>1.56</td><td>0.76&#8211;3.21</td><td/></tr><tr><td/><td>III+</td><td>98 (28.6)</td><td>14 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>I-I</td><td>412 (47.6)</td><td>122 (17.1)</td><td>2.10</td><td>1.52&#8211;2.89</td><td/></tr><tr><td/><td>III+</td><td>160 (46.8)</td><td>99 (17.4)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>I-I</td><td>221 (25.5)</td><td>346 (48.5)</td><td>2.34</td><td>1.74&#8211;3.15</td><td/></tr><tr><td/><td>III+</td><td>81 (23.7)</td><td>299 (52.6)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>I-I</td><td>14 (1.6)</td><td>225 (31.6)</td><td>3.26</td><td>0.92&#8211;11.54</td><td/></tr><tr><td/><td>III+</td><td>3 (0.9)</td><td>156 (27.5)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1207</td><td>1281</td><td/><td/><td/></tr><tr><td/><td><italic>PTPN22</italic></td><td/><td/><td/><td/><td>0.024</td></tr><tr><td>High risk</td><td>TT&#8201;+&#8201;TC</td><td>89 (23.2)</td><td>8 (3.1)</td><td>1.26</td><td>0.55&#8211;2.88</td><td/></tr><tr><td/><td>CC</td><td>237 (27.8)</td><td>27 (2.6)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT&#8201;+&#8201;TC</td><td>177 (46.1)</td><td>55 (21.2)</td><td>1.31</td><td>0.91&#8211;1.86</td><td/></tr><tr><td/><td>CC</td><td>406 (47.7)</td><td>164 (15.6)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT&#8201;+&#8201;TC</td><td>111 (28.9)</td><td>121 (46.7)</td><td>2.44</td><td>1.80&#8211;3.31</td><td/></tr><tr><td/><td>CC</td><td>199 (23.4)</td><td>536 (51.0)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT&#8201;+&#8201;TC</td><td>7 (1.8)</td><td>75 (29.0)</td><td>3.27</td><td>1.18&#8211;9.06</td><td/></tr><tr><td/><td>CC</td><td>9 (1.1)</td><td>323 (30.8)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1235</td><td>1309</td><td/><td/><td/></tr><tr><td/><td><italic>CTLA4</italic></td><td/><td/><td/><td/><td>0.53</td></tr><tr><td>High risk</td><td>TT</td><td>122 (24.9)</td><td>14 (3.6)</td><td>0.90</td><td>0.45&#8211;1.84</td><td/></tr><tr><td/><td>TC-CC</td><td>210 (27.9)</td><td>22 (2.5)</td><td>1</td><td/><td/></tr><tr><td>Intermediate risk</td><td>TT</td><td>241 (49.2)</td><td>65 (16.5)</td><td>1.59</td><td>1.14&#8211;2.23</td><td/></tr><tr><td/><td>TC-CC</td><td>346 (46.0)</td><td>148 (16.7)</td><td>1</td><td/><td/></tr><tr><td>Neutral risk</td><td>TT</td><td>121 (24.7)</td><td>212 (53.8)</td><td>1.34</td><td>1.01&#8211;1.77</td><td/></tr><tr><td/><td>TC-CC</td><td>187 (24.9)</td><td>439 (49.7)</td><td>1</td><td/><td/></tr><tr><td>Low risk</td><td>TT</td><td>6 (1.2)</td><td>103 (26.1)</td><td>1.80</td><td>0.63&#8211;5.18</td><td/></tr><tr><td/><td>TC-CC</td><td>9 (1.2)</td><td>275 (31.1)</td><td>1</td><td/><td/></tr><tr><td>Total</td><td/><td>1242</td><td>1278</td><td/><td/><td/></tr></tbody></table><table-wrap-foot><p textid="29"><italic>n</italic>, Number of cases/controls</p><p textid="30"><sup>a</sup>HLA risk categories: high risk, <italic>DQA1*03-DQB1*0302/DQA1*05-DQB1*0201</italic> (<italic>DQ8/DQ2</italic>), where <italic>DRB1&#8800;0404</italic>; low risk, at least one <italic>DQB1*0602</italic> allele independent of genotype on the other allele; intermediate risk, <italic>DRB1*0404-DQ8/DR3-DQ2</italic>, <italic>DR3-DQ2/DR3-DQ2</italic>, <italic>DR4-DQ8/DR4-DQ8</italic> (excluding homozygous <italic>DRB1 0404</italic>), <italic>DRB1*0401</italic> or <italic>040x-DQ8/X</italic> (X&#8800;<italic>DQB1*0602</italic> or <italic>DR3</italic>). The remaining haplotypes were grouped in the neutral risk category (see Methods)</p><p textid="31"><sup>b</sup>Represents genotypes III/III and I/III</p></table-wrap-foot></table-wrap>
Joint effect of HLA and CTLA4 The ORs for CTLA4 in the different HLA categories (Table 1) indicated no deviation from a two-locus multiplicative model (3 df test; p = 0.53). This was also the case in the trio data set (ESM Table 4) and was supported by the case-only analysis (ESM Table 5; 3 df test; p = 0.57). Again, there was no association between the two loci among controls (3 df test; p = 0.21). Table 1Interaction between HLA-INS (-23HphI), HLA-PTPN22 (Arg620Trp) and HLA-CTLA4 (JO27_1) in the case-control data set using logistic regressionHLA categoryaNon-HLA genotypesCasesControlsOR95% CITest for interaction (p value)n (%)n (%)INSb0.67High riskI-I218 (25.2)20 (2.8)1.560.76-3.21III+98 (28.6)14 (2.5)1Intermediate riskI-I412 (47.6)122 (17.1)2.101.52-2.89III+160 (46.8)99 (17.4)1Neutral riskI-I221 (25.5)346 (48.5)2.341.74-3.15III+81 (23.7)299 (52.6)1Low riskI-I14 (1.6)225 (31.6)3.260.92-11.54III+3 (0.9)156 (27.5)1Total12071281PTPN220.024High riskTT + TC89 (23.2)8 (3.1)1.260.55-2.88CC237 (27.8)27 (2.6)1Intermediate riskTT + TC177 (46.1)55 (21.2)1.310.91-1.86CC406 (47.7)164 (15.6)1Neutral riskTT + TC111 (28.9)121 (46.7)2.441.80-3.31CC199 (23.4)536 (51.0)1Low riskTT + TC7 (1.8)75 (29.0)3.271.18-9.06CC9 (1.1)323 (30.8)1Total12351309CTLA40.53High riskTT122 (24.9)14 (3.6)0.900.45-1.84TC-CC210 (27.9)22 (2.5)1Intermediate riskTT241 (49.2)65 (16.5)1.591.14-2.23TC-CC346 (46.0)148 (16.7)1Neutral riskTT121 (24.7)212 (53.8)1.341.01-1.77TC-CC187 (24.9)439 (49.7)1Low riskTT6 (1.2)103 (26.1)1.800.63-5.18TC-CC9 (1.2)275 (31.1)1Total12421278n, Number of cases/controlsaHLA risk categories: high risk, DQA1*03-DQB1*0302/DQA1*05-DQB1*0201 (DQ8/DQ2), where DRB1not equal0404; low risk, at least one DQB1*0602 allele independent of genotype on the other allele; intermediate risk, DRB1*0404-DQ8/DR3-DQ2, DR3-DQ2/DR3-DQ2, DR4-DQ8/DR4-DQ8 (excluding homozygous DRB1 0404), DRB1*0401 or 040x-DQ8/X (Xnot equalDQB1*0602 or DR3). The remaining haplotypes were grouped in the neutral risk category (see Methods)bRepresents genotypes III/III and I/III
###end p 27
###begin p 28
###xml 20 27 20 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-INS</italic>
###xml 29 36 29 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-23HphI</italic>
###xml 39 49 39 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-PTPN22</italic>
###xml 51 60 51 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Arg620Trp</italic>
###xml 66 75 66 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-CTLA4</italic>
###xml 77 83 77 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">JO27_1</italic>
Interaction between HLA-INS (-23HphI), HLA-PTPN22 (Arg620Trp) and HLA-CTLA4 (JO27_1) in the case-control data set using logistic regression
###end p 28
###begin p 29
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
n, Number of cases/controls
###end p 29
###begin p 30
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 33 68 33 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQA1*03-DQB1*0302/DQA1*05-DQB1*0201</italic>
###xml 70 77 70 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQ8/DQ2</italic>
###xml 86 103 86 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1&#8800;0404</italic>
###xml 128 137 120 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1*0602</italic>
###xml 209 230 201 222 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0404-DQ8/DR3-DQ2</italic>
###xml 232 247 224 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3-DQ2/DR3-DQ2</italic>
###xml 249 264 241 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4-DQ8/DR4-DQ8</italic>
###xml 287 296 279 288 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1 0404</italic>
###xml 299 308 291 300 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRB1*0401</italic>
###xml 312 322 304 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">040x-DQ8/X</italic>
###xml 334 343 318 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DQB1*0602</italic>
###xml 347 350 331 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3</italic>
aHLA risk categories: high risk, DQA1*03-DQB1*0302/DQA1*05-DQB1*0201 (DQ8/DQ2), where DRB1not equal0404; low risk, at least one DQB1*0602 allele independent of genotype on the other allele; intermediate risk, DRB1*0404-DQ8/DR3-DQ2, DR3-DQ2/DR3-DQ2, DR4-DQ8/DR4-DQ8 (excluding homozygous DRB1 0404), DRB1*0401 or 040x-DQ8/X (Xnot equalDQB1*0602 or DR3). The remaining haplotypes were grouped in the neutral risk category (see Methods)
###end p 30
###begin p 31
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bRepresents genotypes III/III and I/III
###end p 31
###begin p 32
###xml 0 29 0 29 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Joint effects of non-HLA loci</bold>
###xml 119 129 119 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22-INS</italic>
###xml 131 134 131 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 135 140 135 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 144 156 144 156 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22-CTLA4</italic>
###xml 189 190 189 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 232 233 232 233 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM5">5</xref>
###xml 240 242 240 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 299 305 299 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 323 325 323 325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 344 345 344 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM6">6</xref>
###xml 512 517 512 517 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 522 528 522 528 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 530 537 530 537 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 557 567 557 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-PTPN22</italic>
###xml 569 578 569 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-CTLA4</italic>
###xml 583 595 583 595 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22-CTLA4</italic>
###xml 537 650 537 650 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="33">Interaction between <italic>INS-PTPN22</italic>, <italic>INS-CTLA4</italic> and <italic>PTPN22-CTLA4</italic> in the case-control data set using logistic regression</p>
###xml 537 650 537 650 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="33">Interaction between <italic>INS-PTPN22</italic>, <italic>INS-CTLA4</italic> and <italic>PTPN22-CTLA4</italic> in the case-control data set using logistic regression</p></caption>
###xml 650 667 650 667 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2" colspan="2">Non-HLA genotypes</th>
###xml 667 672 667 672 <th xmlns:xlink="http://www.w3.org/1999/xlink">Cases</th>
###xml 672 680 672 680 <th xmlns:xlink="http://www.w3.org/1999/xlink">Controls</th>
###xml 680 682 680 682 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">OR</th>
###xml 682 688 682 688 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">95% CI</th>
###xml 708 709 708 709 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 711 712 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 688 719 688 719 <th xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="2">Test for interaction<sup>a</sup> (<italic>p</italic> value)</th>
###xml 650 719 650 719 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th rowspan="2" colspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction<sup>a</sup> (<italic>p</italic> value)</th></tr>
###xml 719 720 719 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 719 724 719 724 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic> (%)</th>
###xml 724 725 724 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 724 729 724 729 <th xmlns:xlink="http://www.w3.org/1999/xlink"><italic>n</italic> (%)</th>
###xml 719 729 719 729 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th><italic>n</italic> (%)</th><th><italic>n</italic> (%)</th></tr>
###xml 650 729 650 729 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th rowspan="2" colspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction<sup>a</sup> (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (%)</th></tr></thead>
###xml 729 732 729 732 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 729 732 729 732 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INS</italic></td>
###xml 732 736 732 736 <td xmlns:xlink="http://www.w3.org/1999/xlink">PTPN</td>
###xml 736 737 736 737 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 737 738 737 738 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 738 739 738 739 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 739 740 739 740 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 740 744 740 744 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="6">0.67</td>
###xml 729 744 729 744 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>INS</italic></td><td>PTPN</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.67</td></tr>
###xml 744 747 744 747 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 747 752 747 752 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT+TC</td>
###xml 752 762 752 762 <td xmlns:xlink="http://www.w3.org/1999/xlink">274 (72.9)</td>
###xml 762 772 762 772 <td xmlns:xlink="http://www.w3.org/1999/xlink">156 (58.4)</td>
###xml 772 776 772 776 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.74</td>
###xml 776 785 776 785 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.38&#8211;2.18</td>
###xml 744 785 744 785 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>I-I</td><td>TT+TC</td><td>274 (72.9)</td><td>156 (58.4)</td><td char="." align="char">1.74</td><td char="." align="char">1.38&#8211;2.18</td></tr>
###xml 785 788 785 788 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 788 790 788 790 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 790 800 790 800 <td xmlns:xlink="http://www.w3.org/1999/xlink">594 (71.6)</td>
###xml 800 810 800 810 <td xmlns:xlink="http://www.w3.org/1999/xlink">587 (54.8)</td>
###xml 810 811 810 811 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 811 812 811 812 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 785 812 785 812 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>I-I</td><td>CC</td><td>594 (71.6)</td><td>587 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr>
###xml 812 816 812 816 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 816 821 816 821 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT+TC</td>
###xml 821 831 821 831 <td xmlns:xlink="http://www.w3.org/1999/xlink">102 (27.1)</td>
###xml 831 841 831 841 <td xmlns:xlink="http://www.w3.org/1999/xlink">111 (41.6)</td>
###xml 841 845 841 845 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.89</td>
###xml 845 854 845 854 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.38&#8211;2.58</td>
###xml 812 854 812 854 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>III+</td><td>TT+TC</td><td>102 (27.1)</td><td>111 (41.6)</td><td char="." align="char">1.89</td><td char="." align="char">1.38&#8211;2.58</td></tr>
###xml 854 858 854 858 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 858 860 858 860 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 860 870 860 870 <td xmlns:xlink="http://www.w3.org/1999/xlink">236 (28.4)</td>
###xml 870 880 870 880 <td xmlns:xlink="http://www.w3.org/1999/xlink">485 (45.2)</td>
###xml 880 881 880 881 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 881 882 881 882 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 854 882 854 882 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>III+</td><td>CC</td><td>236 (28.4)</td><td>485 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr>
###xml 889 890 889 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 882 891 882 891 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total (<italic>n</italic>)</td>
###xml 891 892 891 892 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 892 897 892 897 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,206</td>
###xml 897 902 897 902 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,339</td>
###xml 902 903 902 903 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 903 904 903 904 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 882 904 882 904 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,206</td><td>1,339</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr>
###xml 904 907 904 907 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 904 907 904 907 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>INS</italic></td>
###xml 907 912 907 912 <td xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</td>
###xml 912 913 912 913 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 913 914 913 914 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 914 915 914 915 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 915 916 915 916 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 916 920 916 920 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="6">0.42</td>
###xml 904 920 904 920 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>INS</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.42</td></tr>
###xml 920 923 920 923 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 923 925 923 925 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 925 935 925 935 <td xmlns:xlink="http://www.w3.org/1999/xlink">354 (73.1)</td>
###xml 935 945 935 945 <td xmlns:xlink="http://www.w3.org/1999/xlink">222 (53.9)</td>
###xml 945 949 945 949 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.51</td>
###xml 949 958 949 958 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.23&#8211;1.86</td>
###xml 920 958 920 958 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>I-I</td><td>TT</td><td>354 (73.1)</td><td>222 (53.9)</td><td char="." align="char">1.51</td><td char="." align="char">1.23&#8211;1.86</td></tr>
###xml 958 961 958 961 <td xmlns:xlink="http://www.w3.org/1999/xlink">I-I</td>
###xml 961 966 961 966 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 966 976 966 976 <td xmlns:xlink="http://www.w3.org/1999/xlink">520 (71.0)</td>
###xml 976 986 976 986 <td xmlns:xlink="http://www.w3.org/1999/xlink">492 (54.8)</td>
###xml 986 987 986 987 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 987 988 987 988 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 958 988 958 988 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>I-I</td><td>TC-CC</td><td>520 (71.0)</td><td>492 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr>
###xml 988 992 988 992 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 992 994 992 994 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 994 1004 994 1004 <td xmlns:xlink="http://www.w3.org/1999/xlink">130 (26.9)</td>
###xml 1004 1014 1004 1014 <td xmlns:xlink="http://www.w3.org/1999/xlink">190 (46.1)</td>
###xml 1014 1018 1014 1018 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.31</td>
###xml 1018 1027 1018 1027 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.99&#8211;1.73</td>
###xml 988 1027 988 1027 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>III+</td><td>TT</td><td>130 (26.9)</td><td>190 (46.1)</td><td char="." align="char">1.31</td><td char="." align="char">0.99&#8211;1.73</td></tr>
###xml 1027 1031 1027 1031 <td xmlns:xlink="http://www.w3.org/1999/xlink">III+</td>
###xml 1031 1036 1031 1036 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1036 1046 1036 1046 <td xmlns:xlink="http://www.w3.org/1999/xlink">212 (29.0)</td>
###xml 1046 1056 1046 1056 <td xmlns:xlink="http://www.w3.org/1999/xlink">405 (45.2)</td>
###xml 1056 1057 1056 1057 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1057 1058 1057 1058 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1027 1058 1027 1058 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>III+</td><td>TC-CC</td><td>212 (29.0)</td><td>405 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr>
###xml 1065 1066 1065 1066 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1058 1067 1058 1067 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total (<italic>n</italic>)</td>
###xml 1067 1068 1067 1068 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 1068 1073 1068 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,216</td>
###xml 1073 1078 1073 1078 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,309</td>
###xml 1078 1079 1078 1079 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1079 1080 1079 1080 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1058 1080 1058 1080 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,216</td><td>1,309</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr>
###xml 1080 1084 1080 1084 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN</italic>
###xml 1080 1084 1080 1084 <td xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PTPN</italic></td>
###xml 1084 1089 1084 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</td>
###xml 1089 1090 1089 1090 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 1090 1091 1090 1091 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 1091 1092 1091 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1092 1093 1092 1093 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1093 1097 1093 1097 <td xmlns:xlink="http://www.w3.org/1999/xlink" rowspan="6">0.78</td>
###xml 1080 1097 1080 1097 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td><italic>PTPN</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.78</td></tr>
###xml 1097 1102 1097 1102 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT+TC</td>
###xml 1102 1104 1102 1104 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 1104 1114 1104 1114 <td xmlns:xlink="http://www.w3.org/1999/xlink">143 (29.7)</td>
###xml 1114 1123 1114 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink">75 (17.7)</td>
###xml 1123 1127 1123 1127 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.46</td>
###xml 1127 1136 1127 1136 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.04&#8211;2.05</td>
###xml 1097 1136 1097 1136 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>TT+TC</td><td>TT</td><td>143 (29.7)</td><td>75 (17.7)</td><td char="." align="char">1.46</td><td char="." align="char">1.04&#8211;2.05</td></tr>
###xml 1136 1141 1136 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT+TC</td>
###xml 1141 1146 1141 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1146 1156 1146 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink">239 (31.7)</td>
###xml 1156 1166 1156 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink">183 (20.1)</td>
###xml 1166 1167 1166 1167 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1167 1168 1167 1168 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1136 1168 1136 1168 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>TT+TC</td><td>TC-CC</td><td>239 (31.7)</td><td>183 (20.1)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr>
###xml 1168 1170 1168 1170 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 1170 1172 1170 1172 <td xmlns:xlink="http://www.w3.org/1999/xlink">TT</td>
###xml 1172 1182 1172 1182 <td xmlns:xlink="http://www.w3.org/1999/xlink">339 (70.3)</td>
###xml 1182 1192 1182 1192 <td xmlns:xlink="http://www.w3.org/1999/xlink">348 (82.3)</td>
###xml 1192 1195 1192 1195 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.4</td>
###xml 1195 1204 1195 1204 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.15&#8211;1.67</td>
###xml 1168 1204 1168 1204 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>CC</td><td>TT</td><td>339 (70.3)</td><td>348 (82.3)</td><td char="." align="char">1.4</td><td char="." align="char">1.15&#8211;1.67</td></tr>
###xml 1204 1206 1204 1206 <td xmlns:xlink="http://www.w3.org/1999/xlink">CC</td>
###xml 1206 1211 1206 1211 <td xmlns:xlink="http://www.w3.org/1999/xlink">TC-CC</td>
###xml 1211 1221 1211 1221 <td xmlns:xlink="http://www.w3.org/1999/xlink">514 (68.3)</td>
###xml 1221 1231 1221 1231 <td xmlns:xlink="http://www.w3.org/1999/xlink">729 (79.9)</td>
###xml 1231 1232 1231 1232 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1</td>
###xml 1232 1233 1232 1233 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1204 1233 1204 1233 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>CC</td><td>TC-CC</td><td>514 (68.3)</td><td>729 (79.9)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr>
###xml 1240 1241 1240 1241 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1233 1242 1233 1242 <td xmlns:xlink="http://www.w3.org/1999/xlink">Total (<italic>n</italic>)</td>
###xml 1242 1243 1242 1243 <td xmlns:xlink="http://www.w3.org/1999/xlink">&#160;</td>
###xml 1243 1248 1243 1248 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,235</td>
###xml 1248 1253 1248 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink">1,335</td>
###xml 1253 1254 1253 1254 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1254 1255 1254 1255 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">&#160;</td>
###xml 1233 1255 1233 1255 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,235</td><td>1,335</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr>
###xml 729 1255 729 1255 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td><italic>INS</italic></td><td>PTPN</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.67</td></tr><tr><td>I-I</td><td>TT+TC</td><td>274 (72.9)</td><td>156 (58.4)</td><td char="." align="char">1.74</td><td char="." align="char">1.38&#8211;2.18</td></tr><tr><td>I-I</td><td>CC</td><td>594 (71.6)</td><td>587 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>III+</td><td>TT+TC</td><td>102 (27.1)</td><td>111 (41.6)</td><td char="." align="char">1.89</td><td char="." align="char">1.38&#8211;2.58</td></tr><tr><td>III+</td><td>CC</td><td>236 (28.4)</td><td>485 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,206</td><td>1,339</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr><tr><td><italic>INS</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.42</td></tr><tr><td>I-I</td><td>TT</td><td>354 (73.1)</td><td>222 (53.9)</td><td char="." align="char">1.51</td><td char="." align="char">1.23&#8211;1.86</td></tr><tr><td>I-I</td><td>TC-CC</td><td>520 (71.0)</td><td>492 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>III+</td><td>TT</td><td>130 (26.9)</td><td>190 (46.1)</td><td char="." align="char">1.31</td><td char="." align="char">0.99&#8211;1.73</td></tr><tr><td>III+</td><td>TC-CC</td><td>212 (29.0)</td><td>405 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,216</td><td>1,309</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr><tr><td><italic>PTPN</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.78</td></tr><tr><td>TT+TC</td><td>TT</td><td>143 (29.7)</td><td>75 (17.7)</td><td char="." align="char">1.46</td><td char="." align="char">1.04&#8211;2.05</td></tr><tr><td>TT+TC</td><td>TC-CC</td><td>239 (31.7)</td><td>183 (20.1)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>CC</td><td>TT</td><td>339 (70.3)</td><td>348 (82.3)</td><td char="." align="char">1.4</td><td char="." align="char">1.15&#8211;1.67</td></tr><tr><td>CC</td><td>TC-CC</td><td>514 (68.3)</td><td>729 (79.9)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,235</td><td>1,335</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr></tbody>
###xml 650 1255 650 1255 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction<sup>a</sup> (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (%)</th></tr></thead><tbody><tr><td><italic>INS</italic></td><td>PTPN</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.67</td></tr><tr><td>I-I</td><td>TT+TC</td><td>274 (72.9)</td><td>156 (58.4)</td><td char="." align="char">1.74</td><td char="." align="char">1.38&#8211;2.18</td></tr><tr><td>I-I</td><td>CC</td><td>594 (71.6)</td><td>587 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>III+</td><td>TT+TC</td><td>102 (27.1)</td><td>111 (41.6)</td><td char="." align="char">1.89</td><td char="." align="char">1.38&#8211;2.58</td></tr><tr><td>III+</td><td>CC</td><td>236 (28.4)</td><td>485 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,206</td><td>1,339</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr><tr><td><italic>INS</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.42</td></tr><tr><td>I-I</td><td>TT</td><td>354 (73.1)</td><td>222 (53.9)</td><td char="." align="char">1.51</td><td char="." align="char">1.23&#8211;1.86</td></tr><tr><td>I-I</td><td>TC-CC</td><td>520 (71.0)</td><td>492 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>III+</td><td>TT</td><td>130 (26.9)</td><td>190 (46.1)</td><td char="." align="char">1.31</td><td char="." align="char">0.99&#8211;1.73</td></tr><tr><td>III+</td><td>TC-CC</td><td>212 (29.0)</td><td>405 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,216</td><td>1,309</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr><tr><td><italic>PTPN</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.78</td></tr><tr><td>TT+TC</td><td>TT</td><td>143 (29.7)</td><td>75 (17.7)</td><td char="." align="char">1.46</td><td char="." align="char">1.04&#8211;2.05</td></tr><tr><td>TT+TC</td><td>TC-CC</td><td>239 (31.7)</td><td>183 (20.1)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>CC</td><td>TT</td><td>339 (70.3)</td><td>348 (82.3)</td><td char="." align="char">1.4</td><td char="." align="char">1.15&#8211;1.67</td></tr><tr><td>CC</td><td>TC-CC</td><td>514 (68.3)</td><td>729 (79.9)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,235</td><td>1,335</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr></tbody></table>
###xml 1255 1319 1255 1319 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="34">The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)</p>
###xml 1319 1320 1319 1320 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1319 1462 1319 1462 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35"><sup>a</sup>Likelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locus</p>
###xml 1462 1463 1462 1463 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 1462 1489 1462 1489 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><italic>n</italic>, Number of cases/controls</p>
###xml 1255 1489 1255 1489 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="34">The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)</p><p textid="35"><sup>a</sup>Likelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locus</p><p textid="36"><italic>n</italic>, Number of cases/controls</p></table-wrap-foot>
###xml 530 1489 530 1489 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="33">Interaction between <italic>INS-PTPN22</italic>, <italic>INS-CTLA4</italic> and <italic>PTPN22-CTLA4</italic> in the case-control data set using logistic regression</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" colspan="2">Non-HLA genotypes</th><th>Cases</th><th>Controls</th><th rowspan="2">OR</th><th rowspan="2">95% CI</th><th rowspan="2">Test for interaction<sup>a</sup> (<italic>p</italic> value)</th></tr><tr><th><italic>n</italic> (%)</th><th><italic>n</italic> (%)</th></tr></thead><tbody><tr><td><italic>INS</italic></td><td>PTPN</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.67</td></tr><tr><td>I-I</td><td>TT+TC</td><td>274 (72.9)</td><td>156 (58.4)</td><td char="." align="char">1.74</td><td char="." align="char">1.38&#8211;2.18</td></tr><tr><td>I-I</td><td>CC</td><td>594 (71.6)</td><td>587 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>III+</td><td>TT+TC</td><td>102 (27.1)</td><td>111 (41.6)</td><td char="." align="char">1.89</td><td char="." align="char">1.38&#8211;2.58</td></tr><tr><td>III+</td><td>CC</td><td>236 (28.4)</td><td>485 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,206</td><td>1,339</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr><tr><td><italic>INS</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.42</td></tr><tr><td>I-I</td><td>TT</td><td>354 (73.1)</td><td>222 (53.9)</td><td char="." align="char">1.51</td><td char="." align="char">1.23&#8211;1.86</td></tr><tr><td>I-I</td><td>TC-CC</td><td>520 (71.0)</td><td>492 (54.8)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>III+</td><td>TT</td><td>130 (26.9)</td><td>190 (46.1)</td><td char="." align="char">1.31</td><td char="." align="char">0.99&#8211;1.73</td></tr><tr><td>III+</td><td>TC-CC</td><td>212 (29.0)</td><td>405 (45.2)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,216</td><td>1,309</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr><tr><td><italic>PTPN</italic></td><td>CTLA4</td><td>&#160;</td><td>&#160;</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td><td rowspan="6">0.78</td></tr><tr><td>TT+TC</td><td>TT</td><td>143 (29.7)</td><td>75 (17.7)</td><td char="." align="char">1.46</td><td char="." align="char">1.04&#8211;2.05</td></tr><tr><td>TT+TC</td><td>TC-CC</td><td>239 (31.7)</td><td>183 (20.1)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>CC</td><td>TT</td><td>339 (70.3)</td><td>348 (82.3)</td><td char="." align="char">1.4</td><td char="." align="char">1.15&#8211;1.67</td></tr><tr><td>CC</td><td>TC-CC</td><td>514 (68.3)</td><td>729 (79.9)</td><td char="." align="char">1</td><td char="." align="char">&#160;</td></tr><tr><td>Total (<italic>n</italic>)</td><td>&#160;</td><td>1,235</td><td>1,335</td><td char="." align="char">&#160;</td><td char="." align="char">&#160;</td></tr></tbody></table><table-wrap-foot><p textid="34">The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)</p><p textid="35"><sup>a</sup>Likelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locus</p><p textid="36"><italic>n</italic>, Number of cases/controls</p></table-wrap-foot></table-wrap>
Joint effects of non-HLA loci There was also no indication of deviation from multiplicative two-locus joint effects of PTPN22-INS, INS-CTLA4 or PTPN22-CTLA4 in the case-control data (Table 2) or in the case-only analysis (ESM Table 5) (all p > 0.39). For the trios, the test for interaction between PTPN22 and CTLA4 showed p = 0.046 (ESM Table 6). Taken together with the analysis of the case-control and the case-only data, this weighs against any deviation from a multiplicative two-locus joint effect also of CTLA4 and PTPN22. Table 2Interaction between INS-PTPN22, INS-CTLA4 and PTPN22-CTLA4 in the case-control data set using logistic regressionNon-HLA genotypesCasesControlsOR95% CITest for interactiona (p value)n (%)n (%)INSPTPN    0.67I-ITT+TC274 (72.9)156 (58.4)1.741.38-2.18I-ICC594 (71.6)587 (54.8)1 III+TT+TC102 (27.1)111 (41.6)1.891.38-2.58III+CC236 (28.4)485 (45.2)1 Total (n) 1,2061,339  INSCTLA4    0.42I-ITT354 (73.1)222 (53.9)1.511.23-1.86I-ITC-CC520 (71.0)492 (54.8)1 III+TT130 (26.9)190 (46.1)1.310.99-1.73III+TC-CC212 (29.0)405 (45.2)1 Total (n) 1,2161,309  PTPNCTLA4    0.78TT+TCTT143 (29.7)75 (17.7)1.461.04-2.05TT+TCTC-CC239 (31.7)183 (20.1)1 CCTT339 (70.3)348 (82.3)1.41.15-1.67CCTC-CC514 (68.3)729 (79.9)1 Total (n) 1,2351,335  The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)aLikelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locusn, Number of cases/controls
###end p 32
###begin p 33
###xml 20 30 20 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-PTPN22</italic>
###xml 32 41 32 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-CTLA4</italic>
###xml 46 58 46 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22-CTLA4</italic>
Interaction between INS-PTPN22, INS-CTLA4 and PTPN22-CTLA4 in the case-control data set using logistic regression
###end p 33
###begin p 34
The low-risk genotypes were used as reference (CC, TC-CC, TC-CC)
###end p 34
###begin p 35
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aLikelihood ratio tests of whether the OR conferred by one locus is significantly different over strata defined by genotypes in the other locus
###end p 35
###begin p 36
###xml 0 1 0 1 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
n, Number of cases/controls
###end p 36
###begin p 37
###xml 0 50 0 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Joint effects of more than two susceptibility loci</bold>
###xml 330 332 330 332 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p&#8201;</italic>
###xml 453 454 453 454 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM7">7</xref>
Joint effects of more than two susceptibility loci We also tested models with all three-way and four-way interactions involving the four susceptibility loci using logistic regression (categorising all loci in two groups: increased risk genotypes or not), but none of the multi-way interactions were statistically significant (all p > 0.29). The simultaneous distribution of risk genotypes at all four loci among cases and controls is shown in ESM Table 7. The results show that the more risk loci an individual carries, the higher the relative risk, but the presence or absence of HLA risk loci influences the relative risk much more than the other loci, as expected. For instance, carrying risk genotypes at all three non-HLA loci but not at HLA is associated with a much lower risk than HLA risk genotypes together with low-risk genotypes at all three other loci. The relative risk (OR) conferred by simultaneously carrying high- or moderate-risk HLA and risk genotypes at all the three other loci compared with non-risk-associated genotypes at all four loci was 61. The expected relative risk under a strict multiplicative model involving all four loci was 123 (multiplying all four single-locus effects by each other). The relatively small number of individuals simultaneously carrying all risk genotypes indicates that the observed negative deviation from a four-way multiplicative model was not statistically significant, in accordance with the formal test cited above.
###end p 37
###begin p 38
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink">ROC curve</bold>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 376 377 376 377 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 493 499 493 499 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 757 762 757 762 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 806 812 806 812 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 854 857 854 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 900 903 900 903 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 904 910 904 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 957 960 957 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 961 967 961 967 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 968 973 968 973 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 499 1023 499 1023 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="39">ROC curve for HLA genotypes in four categories and for combinations of genotypes defined by HLA and non-HLA susceptibility loci. The area under the curve (95% confidence interval) was 0.820 (0.803&#8211;0.836) for HLA (dark blue line), 0.828 (0.811&#8211;0.844) for HLA+<italic>CTLA4</italic> (purple line), 0.835 (0.819&#8211;0.851) for HLA+<italic>PTPN22</italic> (grey line), 0.840 (0.824&#8211;0.855) for HLA+<italic>INS</italic> (green line), 0.848 (0.833&#8211;0.863) for HLA+<italic>INS</italic>+<italic>PTPN22</italic> (yellow line) and 0.852 (0.837&#8211;0.867) for HLA+<italic>INS</italic>+<italic>PTPN22</italic>+<italic>CTLA4</italic> (red line). Turquoise dashed line, reference line</p>
###xml 499 1023 499 1023 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="39">ROC curve for HLA genotypes in four categories and for combinations of genotypes defined by HLA and non-HLA susceptibility loci. The area under the curve (95% confidence interval) was 0.820 (0.803&#8211;0.836) for HLA (dark blue line), 0.828 (0.811&#8211;0.844) for HLA+<italic>CTLA4</italic> (purple line), 0.835 (0.819&#8211;0.851) for HLA+<italic>PTPN22</italic> (grey line), 0.840 (0.824&#8211;0.855) for HLA+<italic>INS</italic> (green line), 0.848 (0.833&#8211;0.863) for HLA+<italic>INS</italic>+<italic>PTPN22</italic> (yellow line) and 0.852 (0.837&#8211;0.867) for HLA+<italic>INS</italic>+<italic>PTPN22</italic>+<italic>CTLA4</italic> (red line). Turquoise dashed line, reference line</p></caption>
###xml 1023 1023 1023 1023 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="125_2008_932_Fig1_HTML" id="MO1"/>
###xml 493 1023 493 1023 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="39">ROC curve for HLA genotypes in four categories and for combinations of genotypes defined by HLA and non-HLA susceptibility loci. The area under the curve (95% confidence interval) was 0.820 (0.803&#8211;0.836) for HLA (dark blue line), 0.828 (0.811&#8211;0.844) for HLA+<italic>CTLA4</italic> (purple line), 0.835 (0.819&#8211;0.851) for HLA+<italic>PTPN22</italic> (grey line), 0.840 (0.824&#8211;0.855) for HLA+<italic>INS</italic> (green line), 0.848 (0.833&#8211;0.863) for HLA+<italic>INS</italic>+<italic>PTPN22</italic> (yellow line) and 0.852 (0.837&#8211;0.867) for HLA+<italic>INS</italic>+<italic>PTPN22</italic>+<italic>CTLA4</italic> (red line). Turquoise dashed line, reference line</p></caption><graphic position="anchor" xlink:href="125_2008_932_Fig1_HTML" id="MO1"/></fig>
ROC curve Another way to assess the predictive utility of combinations of genetic risk markers is the ROC curve [40]. This utilises the genotypes of all included individuals and assesses the combination of sensitivity and specificity of different combinations of genotypes. ROC curves for HLA alone, pairwise combinations of HLA and non-HLA loci, and multiple genotypes (Fig. 1) showed an area under the curve of 0.82 for HLA alone, which was only marginally increased by adding non-HLA loci. Fig. 1ROC curve for HLA genotypes in four categories and for combinations of genotypes defined by HLA and non-HLA susceptibility loci. The area under the curve (95% confidence interval) was 0.820 (0.803-0.836) for HLA (dark blue line), 0.828 (0.811-0.844) for HLA+CTLA4 (purple line), 0.835 (0.819-0.851) for HLA+PTPN22 (grey line), 0.840 (0.824-0.855) for HLA+INS (green line), 0.848 (0.833-0.863) for HLA+INS+PTPN22 (yellow line) and 0.852 (0.837-0.867) for HLA+INS+PTPN22+CTLA4 (red line). Turquoise dashed line, reference line
###end p 38
###begin p 39
###xml 258 263 258 263 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 307 313 307 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 355 358 355 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 401 404 401 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 405 411 405 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 458 461 458 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 462 468 462 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
ROC curve for HLA genotypes in four categories and for combinations of genotypes defined by HLA and non-HLA susceptibility loci. The area under the curve (95% confidence interval) was 0.820 (0.803-0.836) for HLA (dark blue line), 0.828 (0.811-0.844) for HLA+CTLA4 (purple line), 0.835 (0.819-0.851) for HLA+PTPN22 (grey line), 0.840 (0.824-0.855) for HLA+INS (green line), 0.848 (0.833-0.863) for HLA+INS+PTPN22 (yellow line) and 0.852 (0.837-0.867) for HLA+INS+PTPN22+CTLA4 (red line). Turquoise dashed line, reference line
###end p 39
###begin p 40
###xml 0 28 0 28 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Age of disease onset and sex</bold>
###xml 235 236 235 236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM8">8</xref>
###xml 241 242 241 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="" rid="MOESM9">9</xref>
Age of disease onset and sex We found no significant deviation from a multiplicative model concerning age-locus and sex-locus interaction for any of the genes. This was confirmed in the trio families and case-only analysis (ESM Tables 8 and 9).
###end p 40
###begin title 41
Discussion
###end title 41
###begin p 42
###xml 224 230 224 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 353 360 353 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-INS</italic>
###xml 362 371 362 371 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-CTLA4</italic>
###xml 373 382 373 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-CTLA4</italic>
###xml 384 394 384 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-PTPN22</italic>
###xml 399 411 399 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22-CTLA4</italic>
###xml 591 592 591 592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">1</xref>
The present study is a comprehensive evaluation of joint effects of the four most well established type 1 diabetes susceptibility genes in both a large case-control series and family material. The relative risk conferred by PTPN22 was stronger in the lower-risk HLA categories than in the high-risk HLA category, while all other two-locus combinations (HLA-INS, HLA-CTLA4, INS-CTLA4, INS-PTPN22 and PTPN22-CTLA4) were consistent with multiplicative models. Although model-free methods have been developed for gene-gene interaction studies, such as multifactor dimensionality reduction (see [1] and references therein), these methods are designed for the detection of novel susceptibility loci, which was not the goal of our investigation.
###end p 42
###begin p 43
###xml 57 63 57 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">27</xref>
###xml 187 189 187 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 240 246 240 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR41">41</xref>
Two of the three previous studies of the joint effect of PTPN22 and HLA were in accordance with our results [25, 27] while the other study found no deviation from a multiplicative model [22]. It should be noted that the interaction between PTPN22 and HLA found in the case-control material and case-only analysis was not replicated in our trio data. One of the reasons for this could be lower statistical power in the trio data. Using the Quanto program ([41]; ), we found that we had more than 80% power to detect significant two-way gene-gene interaction if the true interaction parameter was 0.5. For the trio design we would need as many trios as we had cases in the case-control study to obtain a similar power. Our number of trios was only about a third of the number of cases in the case-control study, with consequently lower power. The case-only design is known to be the most efficient to detect interaction under certain assumptions. For instance, we had >99% power to detect interaction if the true interaction parameter was 0.5.
###end p 43
###begin p 44
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTLA4</italic>
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 267 270 267 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 333 335 333 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">11</xref>
###xml 337 339 337 339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 438 440 438 440 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 578 581 578 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 612 619 612 619 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DR4</italic>
###xml 627 629 627 629 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
The few studies concerning two-locus interaction effects between HLA and CTLA4 and among non-HLA genes [22] have generally indicated multiplicative effects, which is in accordance with our results. Some previous studies have found that the relative risk conferred by INS was similar in subgroups defined by HLA susceptibility genes [11, 12], while three studies have indicated that the effect was stronger in the low risk-HLA categories [16-18], a finding that was only partially supported by our data. On the other hand, one relatively small study has found that the effect of INS was confined to the high-risk HLA-DR4 group [10].
###end p 44
###begin p 45
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">14</xref>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">15</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">10</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">12</xref>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR13">13</xref>
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">16</xref>
###xml 334 336 334 336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 338 340 338 340 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">22</xref>
###xml 342 344 342 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">25</xref>
###xml 731 738 731 738 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR4-DQ8</italic>
###xml 742 749 742 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DR3-DQ2</italic>
###xml 1211 1213 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR42">42</xref>
###xml 1419 1421 1419 1421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR43">43</xref>
###xml 1237 1245 <span type="species:ncbi:9606">patients</span>
The reason for diverging results of the joint effect of established type 1 diabetes susceptibility genes in the literature could be that the studies have been performed with varying sample sizes and with different study designs. Linkage studies [14, 15], case-control association studies [10, 12, 13, 16] and family trio designs [16, 18, 22, 25] have all been used in these studies. Smaller studies might be inadequate to reveal significant interactions. Different criteria for categorising the HLA risk groups could potentially influence the result of the joint effect of HLA and other type 1 diabetes susceptibility genes. However, our conclusions were not affected by alternative classification of HLA risk groups, such as into DR4-DQ8 vs DR3-DQ2 carriers (data not shown). Studies in different populations and ethnic groups have indicated some heterogeneity in HLA-associated risk of type 1 diabetes and it is also possible that gene-gene interactions may vary across populations. However, despite the observed variations in population risk of type 1 diabetes and in HLA haplotype frequencies across populations, the relative predisposing effects of HLA haplotypes seem to be consistent across populations [42]. In our study all the patients were diagnosed before 15 years of age. The fact that the relative risks associated with both risk genotypes and low-risk genotypes seem to diminish with age above 15 years [43] raises the question whether gene-gene interactions may also differ in different age-groups.
###end p 45
###begin p 46
###xml 578 584 578 584 <sub xmlns:xlink="http://www.w3.org/1999/xlink">locus1</sub>
###xml 589 596 589 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink">locus2.</sub>
###xml 674 677 674 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 681 687 681 687 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 992 994 992 994 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR44">44</xref>
###xml 1080 1082 1080 1082 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">18</xref>
###xml 1187 1190 1187 1190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 1367 1370 1367 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 173 185 <span type="species:ncbi:9606">participants</span>
###xml 469 475 <span type="species:ncbi:9606">person</span>
###xml 534 540 <span type="species:ncbi:9606">person</span>
###xml 711 717 <span type="species:ncbi:9606">person</span>
###xml 826 833 <span type="species:ncbi:9606">persons</span>
###xml 1035 1043 <span type="species:ncbi:9606">patients</span>
###xml 1130 1136 <span type="species:ncbi:9606">person</span>
Although no preventive intervention is available for type 1 diabetes today, prediction of disease is an important part of strategies for prevention, both for recruitment of participants for research studies and for identification of target populations for future preventive interventions. Understanding the interacting effect of the established type 1 diabetes susceptibility genes will increase this possibility. In a multiplicative model the relative risk (RR) for a person holding a high-risk genotype at both loci compared with a person with low risk at both loci will be RRlocus1 x RRlocus2. In terms of absolute risk differences, a doubling or tripling of risk due to INS or PTPN22 would be greater for a person with a high-risk HLA genotype than it would for someone with a low-risk HLA genotype. The absolute risk for persons with a given genotype can be estimated by multiplying the average cumulative incidence in the population (0.42% cumulative risk up to age 15 years in Norway [44]) by the ratio of genotype frequency in patients and genotype frequency in controls [18], or using Bayes' formula. For instance, for a person with a low-risk HLA genotype, a high- or low-risk INS genotype will define whether the estimated absolute risk is approximately 0.01% or 0.028% (absolute risk difference, 0.027%), whereas for those with the high-risk HLA genotype INS will define an estimated risk of approximately 3.0% or 4.7% (absolute risk difference 1.7%).
###end p 46
###begin p 47
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR40">40</xref>
###xml 1089 1091 1089 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR45">45</xref>
###xml 1216 1219 1216 1219 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
###xml 1224 1230 1224 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
As discussed in the general setting by Janssens et al. [40], increasing the number of susceptibility loci considered simultaneously generally increases the predictive value for disease. The downside is that the proportion of the population simultaneously carrying multiple risk alleles becomes minute even with a moderate number of susceptibility polymorphisms, and that even with relatively large data sets, as in our study, the absolute risk estimate becomes imprecise. The high-risk HLA genotype is carried by fewer than 3% of population controls, but confers a very high risk of disease. Several practical and scientific aspects of prediction should be considered when evaluating the utility of different prediction regimes. The ROC curve analysis confirms that, despite the higher absolute risk for those few with combinations of several risk markers, adding non-HLA genetic markers only marginally increases the utility of the prediction over that of HLA alone. While up to six susceptibility loci in addition to those studied here have recently been established in type 1 diabetes [45], the magnitude of the effect for each additional locus is very much smaller than that of HLA and even smaller than that of INS and PTPN22, suggesting that they are likely to add only marginally to the prediction of disease in individuals. Furthermore, an informal assessment of the number needed to be genetically screened in order to obtain a cohort of high-risk individuals, which will give rise to a given number of cases of type 1 diabetes, and the costs connected to the genotyping also suggest limited cost-effectiveness in adding non-HLA genetic markers to the prediction regime (data not shown).
###end p 47
###begin p 48
###xml 157 163 157 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN22</italic>
###xml 292 299 292 299 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-INS</italic>
###xml 301 309 301 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-CTLA</italic>
###xml 311 319 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN-INS</italic>
###xml 321 330 321 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS-CTLA4</italic>
###xml 335 345 335 345 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PTPN-CTLA4</italic>
###xml 651 652 651 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-</italic>
In conclusion, in this comprehensive study of interactions among established type 1 diabetes susceptibility genes, we found that the joint effect of HLA and PTPN22 was significantly less than multiplicative in the case-control material, while a multiplicative model could not be rejected for HLA-INS, HLA-CTLA, PTPN-INS, INS-CTLA4 and PTPN-CTLA4. Despite near-multiplicative effects for most loci, and the fact that groups with very high relative risk of type 1 diabetes can be identified by testing for multiple susceptibility genes, only a small proportion of the population (and cases with type 1 diabetes) simultaneously carry HLA and multiple non-HLA susceptibility genotypes.
###end p 48
###begin title 49
Electronic supplementary material
###end title 49
###begin p 50
Below is the link to the electronic supplementary material.
###end p 50
###begin p 51
(PDF 14.3 kb)
###end p 51
###begin p 52
(PDF 110 kb)
###end p 52
###begin p 53
(PDF 69.2 kb)
###end p 53
###begin p 54
(PDF 51.2 kb)
###end p 54
###begin p 55
(PDF 31.9 kb)
###end p 55
###begin p 56
(PDF 48.8 kb)
###end p 56
###begin p 57
(PDF 25.9 kb)
###end p 57
###begin p 58
(PDF 68.0 kb)
###end p 58
###begin p 59
(PDF 25.1 kb)
###end p 59
###begin title 60
Acknowledgement
###end title 60
###begin p 61
###xml 722 725 722 725 <italic xmlns:xlink="http://www.w3.org/1999/xlink">INS</italic>
This work was supported by The National Programme for Research in Functional Genomics in Norway (FUGE), Research Council of Norway, University of Oslo and Eastern Norway Regional Health Authority. G. Joner and L. C. Stene were supported by grants from the Research Council of Norway (148359/330), Norwegian Diabetes Association, Aker Diabetes Research Foundation and Novo Nordisk Fonden. P. R. Njolstad was supported by funds from University of Bergen, and Western Norway Regional Health Authority, Haukeland University Hospital/Innovest, Research Council of Norway (FUGE Programme) and Novo Nordisk Fonden. We thank P. M. Thorsby, J. P. Berg and V. Enge at The Hormone Laboratory, Aker University Hospital, for help with INS genotyping.
###end p 61
###begin p 62
###xml 0 19 0 19 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Duality of interest</bold>
Duality of interest The authors declare that there is no duality of interest associated with this manuscript.
###end p 62
###begin title 63
References
###end title 63
###begin article-title 64
###xml 75 80 <span type="species:ncbi:9606">human</span>
The ubiquitous nature of epistasis in determining susceptibility to common human diseases
###end article-title 64
###begin article-title 65
###xml 88 94 <span type="species:ncbi:9606">humans</span>
Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans
###end article-title 65
###begin article-title 66
A complete enumeration and classification of two-locus disease models
###end article-title 66
###begin article-title 67
A comprehensive review of genetic association studies
###end article-title 67
###begin article-title 68
HLA complex genes in type 1 diabetes and other autoimmune diseases. Which genes are involved?
###end article-title 68
###begin article-title 69
Association of the T cell regulatory gene CTLA4 with susceptibility to autoimmune disease
###end article-title 69
###begin article-title 70
The insulin gene in diabetes
###end article-title 70
###begin article-title 71
A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes
###end article-title 71
###begin article-title 72
Effect modification and the limits of biological inference from epidemiologic data
###end article-title 72
###begin article-title 73
Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility
###end article-title 73
###begin article-title 74
Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals
###end article-title 74
###begin article-title 75
5' Insulin gene polymorphism confers risk to IDDM independently of HLA class II susceptibility
###end article-title 75
###begin article-title 76
Additive susceptibility to insulin-dependent diabetes conferred by HLA-DQB1 and insulin genes
###end article-title 76
###begin article-title 77
Interactive effect of two candidate genes in a disease: extension of the marker-association-segregation chi square method
###end article-title 77
###begin article-title 78
Two-locus maximum lod score analysis of a multifactorial trait: joint consideration of IDDM2 and IDDM4 with IDDM1 in type 1 diabetes
###end article-title 78
###begin article-title 79
In Finland insulin gene region encoded susceptibility to IDDM exerts maximum effect when there is low HLA-DR associated risk
###end article-title 79
###begin article-title 80
###xml 4 9 <span type="species:ncbi:9606">human</span>
The human leukocyte antigen genotype has a modest effect on the insulin gene polymorphism-associated susceptibility to type 1 diabetes in the Finnish population
###end article-title 80
###begin article-title 81
Heterogeneity in the magnitude of the insulin gene effect on HLA risk in type 1 diabetes
###end article-title 81
###begin article-title 82
The language of gene interaction
###end article-title 82
###begin article-title 83
Linkage strategies for genetically complex traits
###end article-title 83
###begin article-title 84
Alternative definitions of epistasis: dependence and interaction
###end article-title 84
###begin article-title 85
Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus
###end article-title 85
###begin article-title 86
CTLA-4 gene polymorphism confers susceptibility to insulin-dependent diabetes mellitus (IDDM) independently from age and from other genetic or immune disease markers
###end article-title 86
###begin article-title 87
Genetic interaction among three genomic regions creates distinct contributions to early- and late-onset type 1 diabetes mellitus
###end article-title 87
###begin article-title 88
Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes
###end article-title 88
###begin article-title 89
Sex-specific association of PTPN22 1858T with type 1 diabetes but not with Hashimoto's thyroiditis or Addison's disease in the German population
###end article-title 89
###begin article-title 90
Association of the PTPN22/LYP gene with type 1 diabetes
###end article-title 90
###begin article-title 91
Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study
###end article-title 91
###begin article-title 92
###xml 142 148 142 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HLA-DQ</italic>
The relation between size at birth and risk of type 1 diabetes is not influenced by adjustment for the insulin gene (-23HphI) polymorphism or HLA-DQ genotype
###end article-title 92
###begin article-title 93
Variation and trends in incidence of childhood diabetes in Europe
###end article-title 93
###begin article-title 94
###xml 66 74 <span type="species:ncbi:9606">children</span>
DNA extraction and HLA genotyping using mailed mouth brushes from children
###end article-title 94
###begin article-title 95
###xml 23 31 <span type="species:ncbi:9606">patients</span>
###xml 92 112 <span type="species:ncbi:10566">human papillomavirus</span>
DQA1 and DQB1 genes in patients with squamous cell carcinoma of the cervix: relationship to human papillomavirus infection and prognosis
###end article-title 95
###begin article-title 96
###xml 70 78 <span type="species:ncbi:9606">children</span>
HLA class II genetic association of type 1 diabetes mellitus in Czech children
###end article-title 96
###begin article-title 97
HLA-DQB1 and -DQA1 typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours
###end article-title 97
###begin article-title 98
HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection
###end article-title 98
###begin article-title 99
Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies
###end article-title 99
###begin article-title 100
The transmission/disequilibrium test: history, subdivision and admixture
###end article-title 100
###begin article-title 101
Pedigree disequilibrium tests for multilocus haplotypes
###end article-title 101
###begin article-title 102
Interaction as departure from additivity in case-control studies: a cautionary note
###end article-title 102
###begin article-title 103
Revisiting the clinical validity of multiplex genetic testing in complex diseases
###end article-title 103
###begin article-title 104
Sample size requirements for association studies of gene-gene interaction
###end article-title 104
###begin article-title 105
Relative predispositional effects of HLA class II DRB1-DQB1 haplotypes and genotypes on type 1 diabetes: a meta-analysis
###end article-title 105
###begin article-title 106
Genetic, autoimmune, and clinical characteristics of childhood- and adult-onset type 1 diabetes
###end article-title 106
###begin article-title 107
###xml 95 103 <span type="species:ncbi:9606">children</span>
Spatiotemporal trends and age-period-cohort modeling of the incidence of type 1 diabetes among children aged <15 years in Norway 1973-1982 and 1989-2003
###end article-title 107
###begin article-title 108
Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes
###end article-title 108
###begin title 109
Abbreviations
###end title 109
###begin p 110
receiver operating characteristic
###end p 110
###begin p 111
single nucleotide polymorphism
###end p 111
###begin p 112
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 112
###begin p 113
The online version of this article (doi:10.1007/s00125-008-0932-0) contains supplementary material, which is available to authorised users.
###end p 113

